<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:EHVVF="http://ehave.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ehvvf-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_EquityPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:EquityPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_TotalEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EquityPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:EquityPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TotalEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EquityPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:EquityPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TotalEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EquityPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:EquityPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TotalEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:EquityPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TotalEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EHVVF:TotalEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BenKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:BenKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BenKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:BenKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MycotopiaConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MycotopiaConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MycotopiaConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BenKaplanMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:BenKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BenKaplanMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:BenKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MycotopiaTherapiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EHVVF:MycotopiaTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EHVVF:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EHVVF:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertiblePromissoryNoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EHVVF:ConvertiblePromissoryNoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-08-032020-08-04_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="From2020-08-032020-08-04_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-02_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-02</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-232019-06-24_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-23</startDate>
            <endDate>2019-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-16_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BenjaminKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BenjaminKaplanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:ExecutiveConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-02_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ChiefTechonologyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:ChiefTechonologyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ChiefTechonologyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:ChiefTechonologyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusOneMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesOneMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusTwoMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesTwoMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusThreeMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesThreeMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusFourMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesFourMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BonusFiveMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:BonusFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MilestonesFiveMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MilestonesFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesOneMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesTwoMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesThreeMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFourMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFiveMember_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MarketCapitalizationMilestonesFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EHVVF:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EHVVF:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MycotopiaCommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EHVVF:MycotopiaCommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-02_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-02_custom_CollaborationAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2020-01-02_custom_CollaborationAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-11-152021-11-16_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-16</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MedicalAdvisoryBoardAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MedicalAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MedicalAdvisoryBoardAgreementsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MedicalAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MedicalAdvisoryBoardAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MedicalAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MedicalAdvisoryBoardAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:MedicalAdvisoryBoardAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-09-142020-09-15_custom_StrategicAllianceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StrategicAllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="From2020-09-142020-09-15_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:PsychedelitechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-15_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EHVVF:PsychedelitechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StrategicAllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:PsychedelitechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:PsychedelitechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-302020-12-31_custom_AssetSaleAndPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:AssetSaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:AssetSaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:AssetSaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AssetSaleAndPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:AssetSaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:FormerAndCurrentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-18</startDate>
            <endDate>2021-01-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EHVVF:FormerAndCurrentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-19</instant>
        </period>
    </context>
    <context id="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:FormerAndCurrentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-18</startDate>
            <endDate>2021-01-19</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EHVVF:ConvertiblePromissoryNoteAndAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_FindersFeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:FindersFeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BenjaminKaplanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:BenjaminKaplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_EhaveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:EhaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MycotopiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MycotopiaMember450651203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:MycotopiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AdvisoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EHVVF:AdvisoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_RejuvIvIncMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EHVVF:RejuvIvIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-08</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-08_custom_RejuvIvIncMember_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EHVVF:RejuvIvIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-08</instant>
        </period>
    </context>
    <context id="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EHVVF:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-08</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-05-27_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-27</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-05-27_us-gaap_SubsequentEventMember_custom_WesanaHealthHoldingsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653606</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EHVVF:WesanaHealthHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31" id="Fact000005">0001653606</dei:EntityCentralIndexKey>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0123">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0125">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:MinorityInterest
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0148"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringPeriodValueCashlessWarrantExercised
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:GainOnForgivenessOfDevelopmentGrant
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:ChangeInFairValueOfDerivativeLiability
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:PurchaseOfFixedAssets
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:PaymentOfConvertibleNotes
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:ProceedsFromRegInvestment
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <EHVVF:CommonStockIssued
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_MedicalEquipmentMember"
      id="xdx2ixbrl0761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0974"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl1123"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1135"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl1153"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl1179"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl1181"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1203"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-12-31" id="Fact000012">20-F/A</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="From2021-01-01to2021-12-31" id="Fact000013">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="From2021-01-01to2021-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-12-31" id="Fact000015">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-12-31" id="Fact000016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-12-31" id="Fact000017">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-12-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2021-01-01to2021-12-31" id="Fact000019">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-12-31" id="Fact000020">333-207107</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31" id="Fact000021">EHAVE, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31" id="Fact000022">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-12-31" id="Fact000023">100 SE 2nd St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine1
      contextRef="From2021-01-012021-12-31_dei_BusinessContactMember"
      id="Fact000024">100 SE 2nd St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-12-31" id="Fact000025">Suite 2000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine2
      contextRef="From2021-01-012021-12-31_dei_BusinessContactMember"
      id="Fact000026">Suite 2000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-12-31" id="Fact000027">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown
      contextRef="From2021-01-012021-12-31_dei_BusinessContactMember"
      id="Fact000028">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-12-31" id="Fact000029">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="From2021-01-012021-12-31_dei_BusinessContactMember"
      id="Fact000030">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-12-31" id="Fact000031">33131</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="From2021-01-012021-12-31_dei_BusinessContactMember"
      id="Fact000032">33131</dei:EntityAddressPostalZipCode>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000033"
      unitRef="Shares">244523925</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-01-01to2021-12-31" id="Fact000034">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-01-01to2021-12-31" id="Fact000035">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-12-31" id="Fact000036">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-12-31" id="Fact000037">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31" id="Fact000038">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31" id="Fact000039">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-12-31" id="Fact000040">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2021-01-01to2021-12-31" id="Fact000041">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2021-01-01to2021-12-31" id="Fact000042">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="From2021-01-01to2021-12-31" id="Fact000043">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-12-31" id="Fact000044">false</dei:EntityShellCompany>
    <dei:AmendmentDescription contextRef="From2021-01-01to2021-12-31" id="Fact000045">Ehave,
Inc. (the &#x201c;Company&#x201d;) filed its Annual Report on Form 20-F for the year ended December 31, 2021, with the Securities and Exchange
Commission (&#x201c;SEC&#x201d;) on May 27, 2022 (the &#x201c;Original Form 20-F&#x201d;). This Amendment No. 1 on Form 20-F/A (&#x201c;Amendment
No. 1&#x201d; or &#x201c;Form 20-F/A&#x201d;) is being filed to reflect the restatement of property and equipment, other assets, accounts
payable and accrued expenses, accrued expenses- related party, current portion of convertible notes, net of debt discount, common stock,
accumulated deficit, non-controlling interest, general and administrative expense, interest expense, amortization expense, net loss from
continuing operations, net loss, loss attributable to the noncontrolling interest, and net loss attributable to Ehave, Inc. stockholders
(the &#x201c;Restatement&#x201d;) in the consolidated balance sheet and statement of operations for the year ended December 31, 2021.</dei:AmendmentDescription>
    <dei:AuditorName contextRef="From2021-01-01to2021-12-31" id="Fact000046">Pinnacle Accountancy Group of Utah</dei:AuditorName>
    <dei:AuditorFirmId contextRef="From2021-01-01to2021-12-31" id="Fact000047">6117</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="From2021-01-01to2021-12-31" id="Fact000048">Farmington, Utah</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2020-01-012020-12-31" id="Fact000049">Turner, Stone &amp; Company, LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="From2020-01-012020-12-31" id="Fact000050">76</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="From2020-01-012020-12-31" id="Fact000051">Dallas, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">2350741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">1865110</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">24247</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">26250</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">26250</us-gaap:ShortTermInvestments>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">50000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">40000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">2426991</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">1955607</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">2497</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">99338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">2528826</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">1955607</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">1783015</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">1299866</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">338000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">50000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">349079</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">1178964</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">222493</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">3299979</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">1921438</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">130147</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">432578</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">3430126</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">2354016</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000121"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">244523925</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">244523925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">67169962</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">67169962</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">27041236</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">17328406</us-gaap:CommonStockValue>
    <EHVVF:EquityPayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">3157789</EHVVF:EquityPayable>
    <EHVVF:EquityPayable
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">1874963</EHVVF:EquityPayable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">-29966387</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">-19729562</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">114597</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">127784</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">347235</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">-398409</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-1248535</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">-901300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">-398409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">2528826</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">1955607</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">9088841</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">3921536</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">9088841</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">3921536</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-9088841</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">-3921536</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">75173</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">141361</us-gaap:InterestExpenseOther>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">2364334</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">804356</us-gaap:AmortizationOfFinancingCosts>
    <EHVVF:GainLossOnSettlementOfDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">46442</EHVVF:GainLossOnSettlementOfDebt>
    <EHVVF:GainLossOnSettlementOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">4179971</EHVVF:GainLossOnSettlementOfDebt>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">-3004387</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">176933</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-2393065</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">406800</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-11481906</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-3514736</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-11481906</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-3514736</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-1245081</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-10236825</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-3514736</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-13187</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-13853</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-13187</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-13853</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-11495093</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-3528589</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">140342653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">140342653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">32622248</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000233"
      unitRef="Shares">32622248</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000243"
      unitRef="Shares">25413920</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">13842414</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-16214826</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">141637</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-2230775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-2230775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">2112765</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">2112765</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">2112765</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">37818154</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">378182</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">378182</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">378182</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">353622</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000263"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">26250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">26250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">26250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <EHVVF:StockIssuedDuringPeriodSharesCashlessWarrantExercised
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">100909</EHVVF:StockIssuedDuringPeriodSharesCashlessWarrantExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">2433357</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">928795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">928795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">928795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">1874963</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">1874963</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">1874963</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-13853</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-13853</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-13853</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-3514736</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-3514736</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">-3514736</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000335"
      unitRef="Shares">67169962</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">17328406</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">1874963</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-19729562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">127784</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-398409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-398409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">67169962</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">17328406</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">1874963</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-19729562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">127784</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-398409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-398409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">3454</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">3454</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">-3454</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <EHVVF:StockIssuedDuringPeriodSharesRegulationAOfferings
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">22682142</EHVVF:StockIssuedDuringPeriodSharesRegulationAOfferings>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">1502000</EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">1502000</EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings>
    <EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">1502000</EHVVF:StockIssuedDuringPeriodValueRegulationAOfferings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">1771864</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">1771864</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">1771864</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">141635524</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">1469004</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">1469004</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000379"
      unitRef="USD">1469004</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <EHVVF:StockIssuedDuringPeriodSharesCashlessWarrantExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000391"
      unitRef="Shares">5681985</EHVVF:StockIssuedDuringPeriodSharesCashlessWarrantExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">7354312</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">7354312</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000409"
      unitRef="USD">4966508</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">1282826</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">1282826</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">1282826</EHVVF:StockIssuedDuringEquityPayableToChiefExecutiveOfficer>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-13187</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-13187</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-13187</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-10236825</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000433"
      unitRef="USD">-10236825</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-1245081</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-11481906</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">-10236825</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-10236825</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">-1245081</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">-11481906</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Shares">244523925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">27041236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">3157789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-29966387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">114597</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">347235</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-1248535</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">-901300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">244523925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">27041236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_custom_EquityPayableMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">3157789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-29966387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">114597</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_custom_TotalEquityMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">347235</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">-1248535</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-901300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-11481906</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">-3514736</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">249</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">4966508</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">928795</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">2364334</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">896348</us-gaap:AmortizationOfDebtDiscountPremium>
    <EHVVF:EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">1282826</EHVVF:EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense>
    <EHVVF:EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">1874963</EHVVF:EquityPayableToChiefExecutiveOfficerRecordedAsOperatingExpense>
    <EHVVF:ImpairmentOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">100000</EHVVF:ImpairmentOfFixedAssets>
    <EHVVF:GainLossOnSettlementOfDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">46442</EHVVF:GainLossOnSettlementOfDebt>
    <EHVVF:GainLossOnSettlementOfDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000490"
      unitRef="USD">4179971</EHVVF:GainLossOnSettlementOfDebt>
    <EHVVF:GainOnForgivenessOfDevelopmentGrant
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">176933</EHVVF:GainOnForgivenessOfDevelopmentGrant>
    <EHVVF:ChangeInFairValueOfDerivativeLiability
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000496"
      unitRef="USD">3004387</EHVVF:ChangeInFairValueOfDerivativeLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">25753</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">-451550</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">488536</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000505"
      unitRef="USD">677576</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">288000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">-2063648</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-38021</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <EHVVF:PurchaseOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">-162084</EHVVF:PurchaseOfFixedAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">-162084</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <EHVVF:PaymentOfPromissoryNotes
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">-302637</EHVVF:PaymentOfPromissoryNotes>
    <EHVVF:PaymentOfPromissoryNotes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000526"
      unitRef="USD">-138561</EHVVF:PaymentOfPromissoryNotes>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1512000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">2238170</us-gaap:ProceedsFromConvertibleDebt>
    <EHVVF:PaymentOfConvertibleNotes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000532"
      unitRef="USD">-141000</EHVVF:PaymentOfConvertibleNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">63500</us-gaap:PaymentsOfFinancingCosts>
    <EHVVF:ProceedsFromRegInvestment
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">-1502000</EHVVF:ProceedsFromRegInvestment>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">2711363</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">1895109</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">-9508</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">485631</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">1847580</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">1865110</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">17530</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">2350741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">1865110</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <EHVVF:CommonStockIssuedForConversionOfDebtAndAccruedInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">1469004</EHVVF:CommonStockIssuedForConversionOfDebtAndAccruedInterest>
    <EHVVF:CommonStockIssuedForConversionOfDebtAndAccruedInterest
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">378182</EHVVF:CommonStockIssuedForConversionOfDebtAndAccruedInterest>
    <us-gaap:StockIssued1
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">40000</us-gaap:StockIssued1>
    <EHVVF:CommonStockIssued
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">26250</EHVVF:CommonStockIssued>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000576">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_ztTShNvL1bf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;1.
&lt;span id="xdx_825_zQw8xCSM9fab"&gt;ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock_zsyYnJ7Po2Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Organization
and General Description of Business&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;EHAVE,
Inc. (formerly known as &#x201c;Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.&#x201d;) (&#x201c;We&#x201d; or
&#x201c;the Company&#x201d;), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic
digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital
assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to
clinicians, patients, researchers, pharmaceutical companies and payors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mycotopia
sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed
by Ehave.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zdpyUppzjrw5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_865_zIl8Pw4Mp7dh"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
amounts have been reclassified for the year ended December 31, 2020 in order to conform to current period presentation. The Company reclassed
$&lt;span id="xdx_90A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember_zbjiJWPZChd3" title="Accounts payable and accrued expenses"&gt;50,000&lt;/span&gt; from accounts payable and accrued expenses to accrued expenses &#x2013; related party for Ben Kaplan&#x2019;s cash compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_zxomDKt2QdB" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_z8VZZRc1yv0d"&gt;Restatement
of Previously Issued Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to the Company&#x2019;s filing of its Annual Report on Form 20-F for the year ended December 31, 2021, with the Securities and Exchange
Commission on May 27, 2022, the Company performed an evaluation of its accounting in connection with the employment agreement entered
into between Mycotopia Therapies, Inc. (&#x201c;Mycotopia&#x201d;), a majority owned subsidiary of the Company, and Ben Kaplan, the Company&#x2019;s
CEO. Management determined that the Original Form 20-F does not give effect to $&lt;span id="xdx_908_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember_z7FELj2DYbD3" title="Cash compensation"&gt;288,000&lt;/span&gt; cash compensation and the issuance of a warrant
(the &#x201c;Warrant&#x201d;) to purchase shares for &lt;span id="xdx_907_ecustom--CommonStockDilutedSharesOutstanding_iI_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_znkDsgkljrTa" title="Percentage of common stock diluted shares outstanding"&gt;5&lt;/span&gt;% of the fully diluted common stock outstanding of Mycotopia. The cash compensation
and Warrant was granted to the Chief Executive Officer of the Company pursuant to his consulting agreement (the &#x201c;Consulting Agreement&#x201d;)
with Mycotopia entered into on November 17, 2021. The Company recorded an additional stock-based compensation expense of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zVHF1k2NyV2" title="Stock based compensation expense"&gt;2,029,861&lt;/span&gt; in
relation to the Warrant. Management concluded on May 12, 2023 that it has identified errors in its calculation of compensation in relation
to the Consulting Agreement. Accordingly, the Company restates its consolidated financial statements in this Form 20-F/A as outlined
further below and in Note 4 &#x2013; Related Party Transactions&lt;i&gt;.&lt;/i&gt; Upon review of the Company&#x2019;s previously filed 20-F, the
following errors were discovered and recorded:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    of $&lt;span id="xdx_908_eus-gaap--OtherAssetsNoncurrent_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zpZCSr7vWlPc"&gt;99,338
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from property and equipment to other asset,
    reduce accumulated depreciation and depreciation expense by $&lt;span id="xdx_90F_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zBe5iHL4QdO1"&gt;39,680
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;associated with the reclass.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
a reduction in accounts payable and accrued expenses of $&lt;span id="xdx_90E_eus-gaap--PaymentsForFees_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z6zJvCjuJqc8"&gt;51,727&lt;/span&gt;,
inclusive of reclass mentioned below&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_903_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zFR25fx3B2z2"&gt;288,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of cash compensation for Ben Kaplan cash
    compensation as accrued expenses &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    $&lt;span id="xdx_90C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zLwLfpR2MpXk" title="Accounts payable and accrued expenses"&gt;50,000&lt;/span&gt; from accounts payable and accrued expenses to accrued expense &#x2013; related party of $&lt;span id="xdx_900_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_znajBh7OgDU5" title="Cash compensation"&gt;50,000&lt;/span&gt; for Ben Kaplan cash compensation
    accrued at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z5tG7JX3XCHf"&gt;55,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zbdvJ1TTI0C3"&gt;55,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of common stock in relation to warrants
    and conversion feature for convertible notes payable entered into.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    $&lt;span id="xdx_902_eus-gaap--MinorityInterest_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zXFtX5XNx6b4" title="Non controlling interest"&gt;861,414&lt;/span&gt; from non-controlling interest to accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    stock based compensation of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zYpCXpO06C8j"&gt;2,149,906&lt;/span&gt;, inclusive of $&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zmD9ZNbpeO7i" title="Warrants valued"&gt;2,029,861&lt;/span&gt; related to the Warrant expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    amortization expense of $&lt;span id="xdx_90C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zruc7MAZ3Vz3"&gt;423,280
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in relation to debt discount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;EHAVE,
INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Expressed
in U.S. Dollars)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_za6NMVADXw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
balance sheets for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zWlUDb4iioei" style="display: none"&gt;SCHEDULE
OF RESTATEMENT ITEMS ON CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSGTwf69cPck" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zie49Gq6ajQh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zy1RWQaLNTKe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_zXgrviMmDif9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Property and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;82,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(79,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,497&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_iI_pp0p0_z1OCV1S02hT6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Other asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0614"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iI_z5RskbrdlnP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zjqcFXebG755" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,834,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,783,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherLiabilitiesCurrent_iI_zxjpZpOT1kp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued expenses &#x2013; related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_z8KdO3gk6506" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Current portion of convertible notes, net of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,067,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,178,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_iI_zWnxbx5zlQ65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,901,941&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,299,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Liabilities_iI_zS2SzSUEVxyb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,032,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,430,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockValue_iI_zU9pzl86Gfqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,631,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,409,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,041,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zdiZy12ezV85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,316,815&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,572&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,966,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockholdersEquity_iI_pp0p0_zIGXymCuHlBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total Ehave, Inc. stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,587,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,239,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MinorityInterest_iI_pp0p0_zD0YVv6cp95c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,109,949&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,248,535&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_zMWAjkxHlBQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(522,912&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(378,388&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(901,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zLlOPj34YOwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
statements of operations and other comprehensive loss for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYxCWv1M4Evh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zGz88r4ds9hl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231_zqG0TkxUfScc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zM8LsGOQDo23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpenses_z4cEslMi6538" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zxaAPHhoSRmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestExpenseOther_iN_di_zxOS9HuX688" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(70,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,220&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AmortizationOfFinancingCosts_iN_di_z7WgTaGvICO5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,941,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(423,280&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,364,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_z9iByXv2r7L2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProfitLoss_pp0p0_zgokId6x2Sef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_z97AcwhCo3oi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Loss attributable to the noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,106,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pp0p0_z1rvkhjbv7Q" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,587,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,573&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,236,825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_pp0p0_zpSJ1FI5W0qd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Comprehensive loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,706,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,495,093&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Basic and diluted net loss per share attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZIjgr222t34" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMUw0dwOcQCj" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztNTEh2EQOXf" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zVAAHY7pi8K" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231_zzwCDpmBlGxk" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_zPpN6FXHoPQh" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJN7HvRfc2Kg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Additionally,
please refer to Note &#x2013; Related Party Transactions, where the Company has included additional disclosure related to the CEO&#x2019;s
consulting agreement with Mycotopia.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zCvKWwfRow19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Basis
of Presentation and principles of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;These
financial statements and related notes are presented in accordance with accounting principles generally accepted in the United
States and are expressed in U.S. dollars. The Company&#x2019;s functional currency is the U.S. Dollar. The Company&#x2019;s fiscal
year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia
Therapies, Inc. (&#x201c;Mycotopia&#x201d;) of which the Company has a &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MycotopiaTherapiesIncMember_zKJcUmQaIbze" title="Ownership percentage"&gt;75.77&lt;/span&gt;%
controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain
reclassifications have been made to the prior period consolidated financial statements to conform to the current period
presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLPm9hvhkTGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Foreign
Currency Translation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
functional currency of the Company&#x2019;s foreign operations is generally the local currency of the country in which the operation is
located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses
are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders&#x2019;
deficit as a component of accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--ForeignCurrencyRiskPolicyTextBlock_zdkhnU6AkKS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Foreign
Currency Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company&#x2019;s
continued financing activities are primarily in United States dollars while the Company&#x2019;s expenditures are in Canadian dollars.
Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3RUcqDrhUx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Cash
and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due
to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents
include cash on-hand and highly-rated U.S. government backed money market fund investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z2mBo0BfbPK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_864_zPfinB1i0Bw9"&gt;Significant
Concentrations and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;maintains its cash in bank
deposit and checking accounts that at times exceed federally insured limits of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20211231_z4IIKWio6ULj" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span id="xdx_909_eus-gaap--ConcentrationRiskCreditRiskFinancialInstruments_c20210101__20211231_zg7Kn73nSuj9" title="Credit risk description"&gt;Approximately $2.1 million is subject to credit
risk at December 31, 2021. However, these cash balances are maintained at creditworthy financial institutions&lt;/span&gt;. The Company has not experienced
any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zDbzcIxCKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Software
Products and Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Software
development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements
to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility
of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through
business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line
method. For the years ended December 31, 2021 and 2020, the Company recorded $&lt;span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPjXJCgYBDqg"&gt;101,633
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and $&lt;span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpuqdJ2bRUD5"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
respectively, as general and administrative expense for software development costs,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zmXNAECezrP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Stock Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We follow ASC Topic 718, &lt;i&gt;Compensation&#x2013;Stock Compensation,&lt;/i&gt;&#160;which prescribes accounting and reporting
standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees
and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their
fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known
as the requisite service period (usually the vesting period).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zN6HGkgVh4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Advertising
Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company expenses advertising costs as incurred. Advertising expense totaled $&lt;span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_z2sBgicAVeo8" title="Advertising expense"&gt;363,450&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AdvertisingExpense_c20200101__20201231_zwSg8hRnw1Id" title="Advertising expense"&gt;0&lt;/span&gt; for the years ended December 31, 2021 and
2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;



&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUsng7qo4wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Impairment
of Long-lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Management
reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their
carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with
the asset are compared with the asset&#x2019;s carrying amount to determine if there has been an impairment, which is calculated as
the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on
expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take
into consideration management&#x2019;s estimates of risk-adjusted discount rates, which ar&lt;/span&gt;e believed to be consistent with
assumptions that marketplace participants would use in their estimates of fair value. During the year ended December 31, 2021, the
Company recorded an impairment on fixed assets in the amount of $&lt;span id="xdx_90B_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zrbInkVX2Bp3" title="Impairment of fixed assets"&gt;100,000&lt;/span&gt;. There were no impairments of property and equipment or
intangible assets recognized during the years ended December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9Jt6LLvEqUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Property
and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;Property
and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line
method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred,
and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets.
During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $&lt;span id="xdx_90E_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zeCW4jFLclT1" title="Impairment of fixed assets"&gt;100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
assets&#x2019; estimated lives used in computing depreciation for property, plant and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BD_zfZIWxHw8kY7" style="display: none"&gt;SCHEDULE
OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZMKq2Nrehcd" title="Property, plant and equipment, useful life"&gt;5
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zQxbKuUl5gkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2021 and 2020, property and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0761"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_znJ5jfeQHb6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zJryjEPpQkbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less,
    accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z6l5FbLMTPc7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJtXUGEjJ498" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of $&lt;span id="xdx_903_eus-gaap--Depreciation_c20210101__20211231_zYhXuxAaKwY3" title="Depreciation"&gt;249&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--Depreciation_dxL_c20200101__20201231_z7on2cMpCXSe" title="Depreciation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zHuxoai4lCM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an
operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments
over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are
classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably
certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $&lt;span id="xdx_908_eus-gaap--ProceedsFromLeasePayments_c20210101__20211231_zrLvvxODEsS6" title="Lease payments"&gt;4,000&lt;/span&gt; per month. For the
year ending December 31, 2021 and 2020, rent expense was $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_c20210101__20211231_zWpdEpbfSW8k" title="Rent expenses"&gt;48,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--PaymentsForRent_c20200101__20201231_z8SWSgKinvE4" title="Rent expenses"&gt;0&lt;/span&gt;. Other than the Company&#x2019;s reimbursement of its CEO for
rent on a month-to-month basis, the Company has not entered into any lease agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zTTdaJpC1Rn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Income
tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts
of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred
tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than
not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized.
Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required
in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates
made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company
to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense
in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in
income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zSRvKMgpcGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Net
Loss per Common Share, basic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company has adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;)
specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per
share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding
for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses
of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zTuY1I1PmNJf"&gt;29,320,478
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares and &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231_zCATv1nbq4wb"&gt;148,428,343
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares issuable upon
the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For
the year ended December 31, 2020, the Company had outstanding warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231_zkCtU5vpeWGb"&gt;28,693,368
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares and &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200101__20201231_z1VO0DzjxzOl"&gt;216,630,546
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares issuable upon the
conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7YwpEm0Ibzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards
Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the
adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <EHVVF:OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000578">&lt;p id="xdx_845_ecustom--OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock_zsyYnJ7Po2Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Organization
and General Description of Business&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;EHAVE,
Inc. (formerly known as &#x201c;Behavioral Neurological Applications and Solutions or 2304101 Ontario Inc.&#x201d;) (&#x201c;We&#x201d; or
&#x201c;the Company&#x201d;), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic
digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital
assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to
clinicians, patients, researchers, pharmaceutical companies and payors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mycotopia
sponsors research and development of the use of psychedelics for the treatment of mental health issues utilizing the technology developed
by Ehave.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</EHVVF:OrganizationAndGeneralDescriptionOfBusinessPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-01-01to2021-12-31" id="Fact000580">&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zdpyUppzjrw5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_865_zIl8Pw4Mp7dh"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
amounts have been reclassified for the year ended December 31, 2020 in order to conform to current period presentation. The Company reclassed
$&lt;span id="xdx_90A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember_zbjiJWPZChd3" title="Accounts payable and accrued expenses"&gt;50,000&lt;/span&gt; from accounts payable and accrued expenses to accrued expenses &#x2013; related party for Ben Kaplan&#x2019;s cash compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_custom_BenKaplanMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">50000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <EHVVF:RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000584">&lt;p id="xdx_84E_ecustom--RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_zxomDKt2QdB" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_z8VZZRc1yv0d"&gt;Restatement
of Previously Issued Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to the Company&#x2019;s filing of its Annual Report on Form 20-F for the year ended December 31, 2021, with the Securities and Exchange
Commission on May 27, 2022, the Company performed an evaluation of its accounting in connection with the employment agreement entered
into between Mycotopia Therapies, Inc. (&#x201c;Mycotopia&#x201d;), a majority owned subsidiary of the Company, and Ben Kaplan, the Company&#x2019;s
CEO. Management determined that the Original Form 20-F does not give effect to $&lt;span id="xdx_908_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember_z7FELj2DYbD3" title="Cash compensation"&gt;288,000&lt;/span&gt; cash compensation and the issuance of a warrant
(the &#x201c;Warrant&#x201d;) to purchase shares for &lt;span id="xdx_907_ecustom--CommonStockDilutedSharesOutstanding_iI_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_znkDsgkljrTa" title="Percentage of common stock diluted shares outstanding"&gt;5&lt;/span&gt;% of the fully diluted common stock outstanding of Mycotopia. The cash compensation
and Warrant was granted to the Chief Executive Officer of the Company pursuant to his consulting agreement (the &#x201c;Consulting Agreement&#x201d;)
with Mycotopia entered into on November 17, 2021. The Company recorded an additional stock-based compensation expense of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zVHF1k2NyV2" title="Stock based compensation expense"&gt;2,029,861&lt;/span&gt; in
relation to the Warrant. Management concluded on May 12, 2023 that it has identified errors in its calculation of compensation in relation
to the Consulting Agreement. Accordingly, the Company restates its consolidated financial statements in this Form 20-F/A as outlined
further below and in Note 4 &#x2013; Related Party Transactions&lt;i&gt;.&lt;/i&gt; Upon review of the Company&#x2019;s previously filed 20-F, the
following errors were discovered and recorded:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    of $&lt;span id="xdx_908_eus-gaap--OtherAssetsNoncurrent_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zpZCSr7vWlPc"&gt;99,338
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from property and equipment to other asset,
    reduce accumulated depreciation and depreciation expense by $&lt;span id="xdx_90F_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zBe5iHL4QdO1"&gt;39,680
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;associated with the reclass.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
a reduction in accounts payable and accrued expenses of $&lt;span id="xdx_90E_eus-gaap--PaymentsForFees_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z6zJvCjuJqc8"&gt;51,727&lt;/span&gt;,
inclusive of reclass mentioned below&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_903_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zFR25fx3B2z2"&gt;288,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of cash compensation for Ben Kaplan cash
    compensation as accrued expenses &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    $&lt;span id="xdx_90C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zLwLfpR2MpXk" title="Accounts payable and accrued expenses"&gt;50,000&lt;/span&gt; from accounts payable and accrued expenses to accrued expense &#x2013; related party of $&lt;span id="xdx_900_eus-gaap--DeferredCompensationCashBasedArrangementsLiabilityCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenKaplanMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_znajBh7OgDU5" title="Cash compensation"&gt;50,000&lt;/span&gt; for Ben Kaplan cash compensation
    accrued at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z5tG7JX3XCHf"&gt;55,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    $&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zbdvJ1TTI0C3"&gt;55,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of common stock in relation to warrants
    and conversion feature for convertible notes payable entered into.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclass
    $&lt;span id="xdx_902_eus-gaap--MinorityInterest_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zXFtX5XNx6b4" title="Non controlling interest"&gt;861,414&lt;/span&gt; from non-controlling interest to accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    stock based compensation of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zYpCXpO06C8j"&gt;2,149,906&lt;/span&gt;, inclusive of $&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zmD9ZNbpeO7i" title="Warrants valued"&gt;2,029,861&lt;/span&gt; related to the Warrant expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Record
    amortization expense of $&lt;span id="xdx_90C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zruc7MAZ3Vz3"&gt;423,280
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in relation to debt discount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;EHAVE,
INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Expressed
in U.S. Dollars)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_za6NMVADXw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
balance sheets for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zWlUDb4iioei" style="display: none"&gt;SCHEDULE
OF RESTATEMENT ITEMS ON CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSGTwf69cPck" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zie49Gq6ajQh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zy1RWQaLNTKe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_zXgrviMmDif9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Property and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;82,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(79,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,497&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_iI_pp0p0_z1OCV1S02hT6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Other asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0614"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iI_z5RskbrdlnP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zjqcFXebG755" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,834,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,783,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherLiabilitiesCurrent_iI_zxjpZpOT1kp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued expenses &#x2013; related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_z8KdO3gk6506" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Current portion of convertible notes, net of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,067,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,178,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_iI_zWnxbx5zlQ65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,901,941&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,299,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Liabilities_iI_zS2SzSUEVxyb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,032,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,430,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockValue_iI_zU9pzl86Gfqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,631,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,409,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,041,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zdiZy12ezV85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,316,815&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,572&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,966,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockholdersEquity_iI_pp0p0_zIGXymCuHlBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total Ehave, Inc. stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,587,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,239,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MinorityInterest_iI_pp0p0_zD0YVv6cp95c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,109,949&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,248,535&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_zMWAjkxHlBQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(522,912&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(378,388&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(901,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zLlOPj34YOwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
statements of operations and other comprehensive loss for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYxCWv1M4Evh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zGz88r4ds9hl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231_zqG0TkxUfScc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zM8LsGOQDo23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpenses_z4cEslMi6538" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zxaAPHhoSRmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestExpenseOther_iN_di_zxOS9HuX688" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(70,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,220&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AmortizationOfFinancingCosts_iN_di_z7WgTaGvICO5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,941,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(423,280&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,364,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_z9iByXv2r7L2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProfitLoss_pp0p0_zgokId6x2Sef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_z97AcwhCo3oi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Loss attributable to the noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,106,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pp0p0_z1rvkhjbv7Q" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,587,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,573&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,236,825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_pp0p0_zpSJ1FI5W0qd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Comprehensive loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,706,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,495,093&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Basic and diluted net loss per share attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZIjgr222t34" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMUw0dwOcQCj" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztNTEh2EQOXf" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zVAAHY7pi8K" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231_zzwCDpmBlGxk" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_zPpN6FXHoPQh" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJN7HvRfc2Kg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Additionally,
please refer to Note &#x2013; Related Party Transactions, where the Company has included additional disclosure related to the CEO&#x2019;s
consulting agreement with Mycotopia.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</EHVVF:RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock>
    <us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent
      contextRef="AsOf2021-12-31_custom_BenKaplanMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">288000</us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent>
    <EHVVF:CommonStockDilutedSharesOutstanding
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="INF"
      id="Fact000588"
      unitRef="Pure">0.05</EHVVF:CommonStockDilutedSharesOutstanding>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">2029861</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">99338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">39680</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsForFees
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000593"
      unitRef="USD">51727</us-gaap:PaymentsForFees>
    <us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent
      contextRef="AsOf2021-12-31_custom_BenKaplanMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000594"
      unitRef="USD">288000</us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_custom_BenKaplanMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000596"
      unitRef="USD">50000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent
      contextRef="AsOf2020-12-31_custom_BenKaplanMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">50000</us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000599"
      unitRef="USD">55000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000600"
      unitRef="USD">55000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000602"
      unitRef="USD">861414</us-gaap:MinorityInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000603"
      unitRef="USD">2149906</us-gaap:ShareBasedCompensation>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000605"
      unitRef="USD">2029861</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000606"
      unitRef="USD">423280</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000608">&lt;p id="xdx_89D_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_za6NMVADXw1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
balance sheets for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zWlUDb4iioei" style="display: none"&gt;SCHEDULE
OF RESTATEMENT ITEMS ON CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSGTwf69cPck" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zie49Gq6ajQh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231_zy1RWQaLNTKe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_zXgrviMmDif9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;Property and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;82,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(79,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,497&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_iI_pp0p0_z1OCV1S02hT6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Other asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0614"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iI_z5RskbrdlnP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zjqcFXebG755" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accounts payable and accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,834,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,783,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherLiabilitiesCurrent_iI_zxjpZpOT1kp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued expenses &#x2013; related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConvertibleDebtCurrent_iI_pp0p0_z8KdO3gk6506" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Current portion of convertible notes, net of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,067,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,178,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_iI_zWnxbx5zlQ65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,901,941&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,299,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Liabilities_iI_zS2SzSUEVxyb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,032,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,430,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockValue_iI_zU9pzl86Gfqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,631,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,409,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,041,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_zdiZy12ezV85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,316,815&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,572&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29,966,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--StockholdersEquity_iI_pp0p0_zIGXymCuHlBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total Ehave, Inc. stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,587,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,239,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MinorityInterest_iI_pp0p0_zD0YVv6cp95c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,109,949&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,248,535&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iI_zMWAjkxHlBQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(522,912&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(378,388&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(901,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zLlOPj34YOwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,528,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the effects of the adjustments on affected items within the Company&#x2019;s previously reported consolidated
statements of operations and other comprehensive loss for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYxCWv1M4Evh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zGz88r4ds9hl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231_zqG0TkxUfScc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Corrected&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zM8LsGOQDo23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingExpenses_z4cEslMi6538" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zxaAPHhoSRmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,681,261&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,407,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,088,841&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestExpenseOther_iN_di_zxOS9HuX688" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(70,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,220&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AmortizationOfFinancingCosts_iN_di_z7WgTaGvICO5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,941,054&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(423,280&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,364,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_z9iByXv2r7L2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProfitLoss_pp0p0_zgokId6x2Sef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,693,748&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,481,906&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_z97AcwhCo3oi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Loss attributable to the noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,106,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(861,414&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_pp0p0_z1rvkhjbv7Q" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,587,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,573&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,236,825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_pp0p0_zpSJ1FI5W0qd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Comprehensive loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,706,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,788,158&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,495,093&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Basic and diluted net loss per share attributable to Ehave, Inc. stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZIjgr222t34" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMUw0dwOcQCj" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ztNTEh2EQOXf" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20210101__20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zVAAHY7pi8K" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20210101__20211231_zzwCDpmBlGxk" title="Basic net loss per share attributable to Ehave Inc stockholders"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20210101__20211231_zPpN6FXHoPQh" title="Diluted net loss per share attributable to Ehave Inc stockholders"&gt;(0.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">82185</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000611"
      unitRef="USD">-79688</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000612"
      unitRef="USD">2497</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000615"
      unitRef="USD">99338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">99338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000618"
      unitRef="USD">2509176</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000619"
      unitRef="USD">19650</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000620"
      unitRef="USD">2528826</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000622"
      unitRef="USD">1834742</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000623"
      unitRef="USD">-51727</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">1783015</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">338000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000628"
      unitRef="USD">338000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000630"
      unitRef="USD">1067199</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">111765</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">1178964</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">2901941</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">398038</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000636"
      unitRef="USD">3299979</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">3032088</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">398038</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000640"
      unitRef="USD">3430126</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">24631466</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000643"
      unitRef="USD">2409770</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">27041236</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">-26316815</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000647"
      unitRef="USD">-3649572</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000648"
      unitRef="USD">-29966387</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000650"
      unitRef="USD">1587037</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-1239802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000652"
      unitRef="USD">347235</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">-2109949</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">861414</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">-1248535</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">-522912</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">-378388</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">-901300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">2509176</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">19650</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">2528826</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000666"
      unitRef="USD">6681261</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000667"
      unitRef="USD">2407580</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000668"
      unitRef="USD">9088841</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000670"
      unitRef="USD">6681261</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">2407580</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">9088841</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">-6681261</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">-2407580</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">-9088841</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000678"
      unitRef="USD">70953</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">4220</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000680"
      unitRef="USD">75173</us-gaap:InterestExpenseOther>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000682"
      unitRef="USD">1941054</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000683"
      unitRef="USD">423280</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">2364334</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000686"
      unitRef="USD">-8693748</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000687"
      unitRef="USD">-2788158</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">-11481906</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">-8693748</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000691"
      unitRef="USD">-2788158</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">-11481906</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000694"
      unitRef="USD">-2106495</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">861414</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">-1245081</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000698"
      unitRef="USD">-6587253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000699"
      unitRef="USD">-3649573</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">-10236825</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">-8706935</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact000703"
      unitRef="USD">-2788158</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">-11495093</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact000706"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact000708"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="Fact000710"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="Fact000712"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000718">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zCvKWwfRow19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Basis
of Presentation and principles of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;These
financial statements and related notes are presented in accordance with accounting principles generally accepted in the United
States and are expressed in U.S. dollars. The Company&#x2019;s functional currency is the U.S. Dollar. The Company&#x2019;s fiscal
year-end is December 31. The consolidated financial statements include the amounts of the Company and its subsidiary, Mycotopia
Therapies, Inc. (&#x201c;Mycotopia&#x201d;) of which the Company has a &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MycotopiaTherapiesIncMember_zKJcUmQaIbze" title="Ownership percentage"&gt;75.77&lt;/span&gt;%
controlling ownership interest. All inter-company accounts and transaction have been eliminated in consolidation. Certain
reclassifications have been made to the prior period consolidated financial statements to conform to the current period
presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-12-31_custom_MycotopiaTherapiesIncMember"
      decimals="INF"
      id="Fact000720"
      unitRef="Pure">0.7577</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000722">&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLPm9hvhkTGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Foreign
Currency Translation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
functional currency of the Company&#x2019;s foreign operations is generally the local currency of the country in which the operation is
located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Expenses
are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders&#x2019;
deficit as a component of accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <EHVVF:ForeignCurrencyRiskPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000724">&lt;p id="xdx_840_ecustom--ForeignCurrencyRiskPolicyTextBlock_zdkhnU6AkKS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Foreign
Currency Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company&#x2019;s
continued financing activities are primarily in United States dollars while the Company&#x2019;s expenditures are in Canadian dollars.
Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</EHVVF:ForeignCurrencyRiskPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000726">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3RUcqDrhUx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Cash
and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due
to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents
include cash on-hand and highly-rated U.S. government backed money market fund investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-01-01to2021-12-31" id="Fact000728">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z2mBo0BfbPK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_864_zPfinB1i0Bw9"&gt;Significant
Concentrations and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;maintains its cash in bank
deposit and checking accounts that at times exceed federally insured limits of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20211231_z4IIKWio6ULj" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span id="xdx_909_eus-gaap--ConcentrationRiskCreditRiskFinancialInstruments_c20210101__20211231_zg7Kn73nSuj9" title="Credit risk description"&gt;Approximately $2.1 million is subject to credit
risk at December 31, 2021. However, these cash balances are maintained at creditworthy financial institutions&lt;/span&gt;. The Company has not experienced
any losses in such accounts and believes it is not exposed to any significant credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstruments contextRef="From2021-01-01to2021-12-31" id="Fact000732">Approximately $2.1 million is subject to credit
risk at December 31, 2021. However, these cash balances are maintained at creditworthy financial institutions</us-gaap:ConcentrationRiskCreditRiskFinancialInstruments>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000734">&lt;p id="xdx_84D_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zDbzcIxCKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Software
Products and Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Software
development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements
to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility
of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through
business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line
method. For the years ended December 31, 2021 and 2020, the Company recorded $&lt;span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPjXJCgYBDqg"&gt;101,633
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and $&lt;span id="xdx_907_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpuqdJ2bRUD5"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
respectively, as general and administrative expense for software development costs,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Fact000735"
      unitRef="USD">101633</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000738">&lt;p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zmXNAECezrP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Stock Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We follow ASC Topic 718, &lt;i&gt;Compensation&#x2013;Stock Compensation,&lt;/i&gt;&#160;which prescribes accounting and reporting
standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees
and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their
fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known
as the requisite service period (usually the vesting period).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000740">&lt;p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zN6HGkgVh4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Advertising
Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company expenses advertising costs as incurred. Advertising expense totaled $&lt;span id="xdx_90E_eus-gaap--AdvertisingExpense_c20210101__20211231_z2sBgicAVeo8" title="Advertising expense"&gt;363,450&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AdvertisingExpense_c20200101__20201231_zwSg8hRnw1Id" title="Advertising expense"&gt;0&lt;/span&gt; for the years ended December 31, 2021 and
2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;



</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">363450</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000746">&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zUsng7qo4wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Impairment
of Long-lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Management
reviews long-lived assets that are held and used for impairment whenever events or changes in circumstances indicate that their
carrying amounts may not be recoverable. If an evaluation is required, the estimated future undiscounted cash flows associated with
the asset are compared with the asset&#x2019;s carrying amount to determine if there has been an impairment, which is calculated as
the difference between the fair value of an asset and its carrying value. Estimates of future undiscounted cash flows are based on
expected growth rates for the business, anticipated future economic conditions and estimates of residual values. Fair values take
into consideration management&#x2019;s estimates of risk-adjusted discount rates, which ar&lt;/span&gt;e believed to be consistent with
assumptions that marketplace participants would use in their estimates of fair value. During the year ended December 31, 2021, the
Company recorded an impairment on fixed assets in the amount of $&lt;span id="xdx_90B_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zrbInkVX2Bp3" title="Impairment of fixed assets"&gt;100,000&lt;/span&gt;. There were no impairments of property and equipment or
intangible assets recognized during the years ended December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <EHVVF:ImpairmentOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">100000</EHVVF:ImpairmentOfFixedAssets>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000750">&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9Jt6LLvEqUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Property
and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;Property
and equipment is recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight-line
method of the estimated useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred,
and expenditures for betterments and major improvements are capitalized and depreciated over the remaining useful lives of the assets.
During the year ended December 31, 2021, the Company recorded an impairment on fixed assets in the amount of $&lt;span id="xdx_90E_ecustom--ImpairmentOfFixedAssets_c20210101__20211231_zeCW4jFLclT1" title="Impairment of fixed assets"&gt;100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
assets&#x2019; estimated lives used in computing depreciation for property, plant and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BD_zfZIWxHw8kY7" style="display: none"&gt;SCHEDULE
OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZMKq2Nrehcd" title="Property, plant and equipment, useful life"&gt;5
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zQxbKuUl5gkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2021 and 2020, property and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0761"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_znJ5jfeQHb6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zJryjEPpQkbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less,
    accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z6l5FbLMTPc7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJtXUGEjJ498" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the years ending December 31, 2021 and 2020, the Company recorded depreciation expense of $&lt;span id="xdx_903_eus-gaap--Depreciation_c20210101__20211231_zYhXuxAaKwY3" title="Depreciation"&gt;249&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--Depreciation_dxL_c20200101__20201231_z7on2cMpCXSe" title="Depreciation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <EHVVF:ImpairmentOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">100000</EHVVF:ImpairmentOfFixedAssets>
    <EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000754">&lt;p id="xdx_891_ecustom--ScheduleOfEstimatedUsefulLifeTableTextBlock_z3rJdVTl03G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
assets&#x2019; estimated lives used in computing depreciation for property, plant and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BD_zfZIWxHw8kY7" style="display: none"&gt;SCHEDULE
OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZMKq2Nrehcd" title="Property, plant and equipment, useful life"&gt;5
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EHVVF:ScheduleOfEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember"
      id="Fact000756">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000758">&lt;p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS1Hm9Q7frSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2021 and 2020, property and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B3_zD4a7Dfq2jfd" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49B_20211231_zDOaqTpo7xu9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49A_20201231_z8tY7SAtG536" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zuFJSbvdxgLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0761"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz8pC_znJ5jfeQHb6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,746&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz8pC_zJryjEPpQkbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less,
    accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz8pC_z6l5FbLMTPc7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; color: Black; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">2746</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">2746</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">249</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000769"
      unitRef="USD">2497</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">249</us-gaap:Depreciation>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000776">&lt;p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zHuxoai4lCM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
Company reviews all arrangements for potential leases in accordance with ASC 842, and at inception, determines whether a lease is an
operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments
over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are
classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably
certain to be exercised. The Company reimburses its CEO, Ben Kaplan, for leased office space in the amount of $&lt;span id="xdx_908_eus-gaap--ProceedsFromLeasePayments_c20210101__20211231_zrLvvxODEsS6" title="Lease payments"&gt;4,000&lt;/span&gt; per month. For the
year ending December 31, 2021 and 2020, rent expense was $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_c20210101__20211231_zWpdEpbfSW8k" title="Rent expenses"&gt;48,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--PaymentsForRent_c20200101__20201231_z8SWSgKinvE4" title="Rent expenses"&gt;0&lt;/span&gt;. Other than the Company&#x2019;s reimbursement of its CEO for
rent on a month-to-month basis, the Company has not entered into any lease agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ProceedsFromLeasePayments
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">4000</us-gaap:ProceedsFromLeasePayments>
    <us-gaap:PaymentsForRent
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">48000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">0</us-gaap:PaymentsForRent>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000784">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zTTdaJpC1Rn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Income
tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts
of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred
tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than
not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized.
Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required
in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates
made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company
to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense
in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in
income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000786">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zSRvKMgpcGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Net
Loss per Common Share, basic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company has adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) subtopic 260-10, Earnings Per Share (&#x201c;ASC 260-10&#x201d;)
specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per
share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding
for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses
of the entity. For the year ended December 31, 2021, the Company had outstanding warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zTuY1I1PmNJf"&gt;29,320,478
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares and &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231_zCATv1nbq4wb"&gt;148,428,343
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares issuable upon
the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. For
the year ended December 31, 2020, the Company had outstanding warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231_zkCtU5vpeWGb"&gt;28,693,368
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares and &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200101__20201231_z1VO0DzjxzOl"&gt;216,630,546
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;common shares issuable upon the
conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">29320478</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">148428343</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">28693368</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000790"
      unitRef="Shares">216630546</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000792">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7YwpEm0Ibzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the periods ended December 31, 2021 and 2020 there were several new accounting pronouncements issued by the Financial Accounting Standards
Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the
adoption of any of these accounting pronouncements has had or will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000794">&lt;p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zqsTKmn9uLFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;2.
&lt;span id="xdx_822_z60LLl0ThxRg"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States,
which contemplate the continuation of the Company as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Through
December 31, 2021, the Company has incurred an accumulated deficit of $&lt;span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zusXbNxGmL01"&gt;29,966,387&lt;/span&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;primarily as a result of expenses
incurred through a combination of development and commercialization activities related to our products and general and administrative
expenses supporting those activities, as well as an operating loss of $&lt;span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20210101__20211231_z5dn5290xxKi"&gt;9,088,841
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;for the year ended December
31, 2021. Our total cash balance as of December 31, 2021 was $&lt;span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_z2n23ah0JTy3"&gt;2,350,741&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
At December 31, 2021, we had a working capital deficit of $&lt;span id="xdx_904_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20211231_zoFMx1nroc2c"&gt;872,988&lt;/span&gt;.
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;We anticipate that we will
continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As
a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient
resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about
our ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To further improve the Company&#x2019;s liquidity position, the Company&#x2019;s management continues to explore additional
equity and debt financing through discussions with investment bankers and private investors. Further, the Company&#x2019;s management continues
to explore strategic acquisitions in order to achieve profitability. There can be no assurance that the company will be successful in
its effort to secure additional financing. The financial statements do not include any adjustments relating to the recoverability of assets
and the amount or classification of liabilities that might be necessary should the company be unable to continue as a going concern.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000795"
      unitRef="USD">-29966387</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">-9088841</us-gaap:OperatingIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000797"
      unitRef="USD">2350741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <EHVVF:WorkingCapitalDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">872988</EHVVF:WorkingCapitalDeficit>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000800">&lt;p id="xdx_801_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zjA5ihXZILP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;3.
&lt;span id="xdx_827_zWlp7XQZJKVg"&gt;FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;ASC
Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that
prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level
3 measurements). Other current assets, accounts payable and accrued expenses, and convertible notes are all stated at book value due
to the term and nature of such items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000802">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zH7mzfCdAVL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;4.
&lt;span id="xdx_82D_zXmL0W3U7PUf"&gt;RELATED PARTY TRANSACTIONS &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of
$&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_pp0p0" title="Debt instrument, principal amount"&gt;11,000&lt;/span&gt;,
in the aggregate, including $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_pp0p0" title="Debt original issue discount"&gt;1,000&lt;/span&gt;
of original issue discount and &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_zZcnuXrhbbOf" title="Aggregate of warrants"&gt;110,000&lt;/span&gt;
warrants, in the aggregate, with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteThreeMember_zuvv0uSvFRQ3" title="Warrants exercise price"&gt;0.01&lt;/span&gt;
per share. During the year ended December 31, 2021, this note was converted into &lt;span id="xdx_907_eus-gaap--CommonStockDividendsShares_pid_c20210101__20211231_zi32McH4iHOi" title="Conversion of common stock"&gt;110,000&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
August 4, 2020, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200803__20200804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyMember_z9yCxzAFsXgg" title="Number of shares issued for services, shares"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200803__20200804__srt--TitleOfIndividualAxis__custom--DirectorsMember_zxZ53FRD8tO9" title="Number of shares issued for services, shares"&gt;775,194&lt;/span&gt;&lt;/span&gt; shares of common stock, in the aggregate, to two individuals who are a related party and directors
of the Company for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="text-decoration: underline"&gt;Ehave
Consulting Agreement with the CEO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 1, 2021, the Company entered into an Executive Consulting Agreement, which superseded the previous consulting agreement, with
Benjamin Kaplan to serve as the Company&#x2019;s CEO for an initial term of &lt;span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zHoxzQ0IrxX" title="Term of notes"&gt;36&lt;/span&gt; months. As of December 31, 2021 and 2020, the Company has
recorded $&lt;span id="xdx_900_eus-gaap--InterestExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zY3K9xJKevI" title="Interest expenses"&gt;210,900&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--InterestExpense_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zINIrCrcDdF7" title="Interest expenses"&gt;320,000&lt;/span&gt;, respectively, as accrued expense in relation to the Executive Consulting Agreement. As of December 31,
2021 and 2020, the Company has accrued $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zDjlJSTdnXO" title="Interest expenses on debt"&gt;3,157,789&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zzMXYOZrAGWg" title="Interest expenses on debt"&gt;1,874,963&lt;/span&gt;, respectively, as equity payable in relation to the Executive Consulting
Agreement. During the years ending December 31, 2021 and 2020, the Company has recorded $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zmvv3pwf2ANc" title="Repayments to related party debt"&gt;1,691,226&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_pp0p0" title="Repayments to related party debt"&gt;2,194,963&lt;/span&gt; as general and administrative
expense in relation to the executive consulting agreement. During the year ending December 31, 2021, the Company paid $&lt;span id="xdx_904_eus-gaap--PaymentsToEmployees_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z6GzxRIzdVAk" title="Payments to CEO"&gt;517,500&lt;/span&gt; to the
CEO in relation to the Executive Consulting Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company&#x2019;s
CEO for an initial term of &lt;span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtM_c20190623__20190624__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_znkWl0co1so9" title="Term of notes"&gt;24&lt;/span&gt; months. In addition to the monthly consulting fee, the Agreement provides for a one month &#x2018;termination
fee&#x2019; if the Agreement is terminated without cause.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
June 29, 2019, the Company and BK amended the Agreement as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;BK
was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common
shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zQgjBpQzTuh9" title="Warrants exercise price"&gt;0.01&lt;/span&gt; USD per share and shall expire
&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200416__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z3Rg9HSsfur" title="Warrant expiry date"&gt;April 16, 2022&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zCoqWTic4KZc" title="Shares issued upon exercise of warrants"&gt;3,358,498&lt;/span&gt; vested warrants to Ben Kaplan, the Company&#x2019;s CEO, in accordance
with his employment agreement valued at $&lt;span id="xdx_90A_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_pdp0_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zmWQ3ccprVf6" title="Warrants issued during period, value"&gt;720,695&lt;/span&gt; (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
the closing of a Significant Transaction (defined as the closing of financing for at least $&lt;span id="xdx_905_eus-gaap--PaymentForContingentConsiderationLiabilityFinancingActivities_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Payment for contingent consideration"&gt;500,000&lt;/span&gt; or the closing of an acquisition
with a valuation (determined by the value of the consideration paid by the Company) of not less than $&lt;span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Payment of consideration for rendered services"&gt;1,000,000&lt;/span&gt; USD), BK would be granted
a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued
or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned
by BK for each Significant Transaction closed during the term of the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 1, 2021, the Company entered into a new consulting agreement with the CEO for a term of &lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtM_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zN67zSY8xV46"&gt;36&lt;/span&gt; months and will automatically renew
for an additional 12 months. Compensation under the January 1, 2021 agreement is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Annual
Salary Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company shall pay the CEO a fee of $&lt;span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zyuMb19qwj7h"&gt;24,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;per month as annual salary compensation.
During the year ended December 31, 2021, the Company recorded $&lt;span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuCvDfZl8ag1"&gt;288,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;as general and administrative expense
for the CEO fee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Bonus&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zjkKxneFkRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year
ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B7_zJJp43T5yRu7" style="display: none"&gt;SCHEDULE
OF BONUS AND MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus
    (Canadian Dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;EBITDA
    Milestones (Canadian Dollars)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 40%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zyqifyjtB7T5" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1&lt;sup&gt;st
    &lt;/sup&gt;$&lt;span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember_zERmxAD2OCwh" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zxPo2QkPlvVc"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2&lt;sup&gt;nd
    &lt;/sup&gt;$&lt;span id="xdx_90E_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember_zH6FBzSbrnJg"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zBh1b2i6K0Qj"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3&lt;sup&gt;rd
    &lt;/sup&gt;$&lt;span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember_ziiK0GmQG0R1"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zeUUPl0HJ957"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4&lt;sup&gt;th
    &lt;/sup&gt;$&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember_ziWQA0jQI0u4"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zN5PmOdmdYz5"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5&lt;sup&gt;th
    &lt;/sup&gt;$&lt;span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember_zoSKPsJIyTpe" title="EBITDA Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zbeLJ2RudWlk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zdyOOOaagc74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining
the below market cap for a period of 22 consecutive trading days:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BC_zQsWSfHCx7Zc" style="display: none"&gt;SCHEDULE
OF BONUS AND MARKET CAPITALIZATION MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus
    (Shares)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    Capitalization Milestone (U.S. Dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98F_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zTC7LBZqvwg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 41%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 54%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zQuyMa50iioj"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zkZpGnShiQoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zmHPa3NpaURc"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98D_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zbpj6AEICy8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zu9cVbuPKXC"&gt;60,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zc53F3qNrRWb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_zzNrcLEyAHU3" title="Market Capitalization Milestone"&gt;80,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zkpS9cN0kXdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zEJQ4hy4S01a" title="Market Capitalization Milestone"&gt;100,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zAC6YgbAoDWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Stock
Grants &#x2013; Significant Transactions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Upon
the Company closing of a Significant Transaction, the CEO shall be granted shares of common stock or new series of preferred shares of
the Company that is convertible into common stock equal to 10% of the value of all the consideration, including any stock, cash or debt
of such completed transaction. The CEO shall earn this grant for each Significant Transaction closed by the Company. A &#x201c;Significant
Transaction&#x201d; shall mean a licensing transaction, merger with or acquisition of an operating company in a strategic or synergistic
line of business, and a financing or direct or indirect share issuance transaction involving the Company, which as a whole, provides
cash flow or equivalent value in excess of $&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20210101__20211231_zIV09zjVr8U6" title="Payments cashflows"&gt;250,000&lt;/span&gt;. For the years ending December 31, 2021 and 2020, the Company accrued $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z1pm0M8vzlza" title="General and administrative expenses"&gt;1,282,826&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z2uOQyj66Rrk"&gt;1,874,963&lt;/span&gt;, respectively, as equity payable in relation to the Significant Transaction milestones being met. These amounts were recorded
as general and administrative expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Equity
Payable to Chief Executive Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2021 and 2020, the Company had a balance of $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zFMnspTUbmrk"&gt;3,157,789
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and $&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_zEMY0SzKo559"&gt;1,874,963&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
respectively, as equity payable for Significant Transactions. During the years ended December 31, 2021 and 2020, the Company recorded
$&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z0suVJUGVN98"&gt;1,282,826
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and $&lt;span id="xdx_909_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember_z0Jny0Gz7dkd"&gt;1,874,963&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
respectively, as general and administrative expense for Significant Transactions entered into during the periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;Mycotopia Consulting Agreement
with the CEO&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2021, Mycotopia
entered into an Executive Consulting Agreement (the &#x201c;Mycotopia Consulting Agreement&#x201d;), with Benjamin Kaplan (&#x201c;BK&#x201d;)
to serve as the Company&#x2019;s CEO for an initial term of&#160;36&#160;months. As of December 31, 2021, the Company recorded $&lt;span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zQnWGoZTEabj" title="Accrued expense"&gt;288,000&lt;/span&gt;
for cash compensation as accrued expense - related party in relation to the Mycotopia Consulting Agreement. During the year ending December
31, 2021, the Company recorded $&lt;span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zNMyKblSrfoj" title="General and administrative expense"&gt;2,317,861&lt;/span&gt; as general and administrative expense, of which $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zoJeX5scnHHe" title="Stock based compensation expensee"&gt;2,029,861&lt;/span&gt; was recorded as stock-based compensation
in relation to the Warrant issued in connection with the Mycotopia Consulting Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant terms of the
Mycotopia Consulting Agreement are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;BK was granted a Warrant
to purchase that number of shares of Mycotopia common stock equal to 5% of the issued and outstanding Mycotopia common shares, on a fully
diluted basis. The Warrant has an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zhlNqMEADiKk" title="Warrant exercise price"&gt;0.01&lt;/span&gt; per share and shall expire&#160;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zduvDi1uuX44" title="Warrant expiration date"&gt;November 16, 2023&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December
31, 2021, the Company issued&#160;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zKTsTRHTC6jg" title="Vested"&gt;812,118&lt;/span&gt;&#160;vested Mycotopia warrants in accordance with the Warrant valued at $&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zyCncHujzcRi" title="Warrants valued"&gt;2,029,861&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Bonus&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDebtTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zqgOnLNSHdt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company will &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;pay
the CEO a bonus in Mycotopia restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending
December 31, 2021, no EBITDA milestones were met, and no amounts have been recorded for the bonus milestones.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B3_zFYU8omL00F1" style="display: none"&gt;SCHEDULE
OF BONUS AND MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;EBITDA Milestones&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zZOK7ixDxO76" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;sup&gt;st&#160;&lt;/sup&gt;$&lt;span id="xdx_90A_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zAzTsBYMxlEb" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z2HGvpWSczo7" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;sup&gt;nd&#160;&lt;/sup&gt;$&lt;span id="xdx_90D_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zLzLeDET2ga3" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zBcbEvbsZwUi" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;sup&gt;rd&#160;&lt;/sup&gt;$&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_znpoWkz3Pofb" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zknu04Yws25f" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4&lt;sup&gt;th&#160;&lt;/sup&gt;$&lt;span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zAiwOxRgb3Oc" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zNGBUufhUhPb"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;sup&gt;th&#160;&lt;/sup&gt;$&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zYnPRCnWKa73" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_z03hvuNCn42k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zsOxn9MN936k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Mycotopia market capitalization
by maintaining the below market cap for Mycotopia for a period of 22 consecutive trading days:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B5_z66kon1cClug" style="display: none"&gt;SCHEDULE
OF BONUS AND MARKET CAPITALIZATION MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Bonus (Shares)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Market Capitalization Milestone&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_984_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zSHg0NOOdhp6" style="width: 41%" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 54%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z1loD84Y3v4g" title="Market Capitalization Milestone"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_984_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zxmHN03BLKO7" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zi0ZuDNxeKb7" title="Market Capitalization Milestone"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zSKFOkd2BFGh" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z6lbaChMdMP4" title="Market Capitalization Milestone"&gt;60,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_98E_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zrYAZIxgIUpa" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z9JSK54ReQ43" title="Market Capitalization Milestone"&gt;80,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98C_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z8nh8QDjM6Vh" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zXpEB65X9kdb" title="Market Capitalization Milestone"&gt;100,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_ztLXyJlYZZfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Stock Grants &#x2013;&#160;Significant
Transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon the Company closing
of a Significant Transaction with Mycotopia, the CEO shall be granted shares of Mycotopia common stock or new series of Mycotopia preferred
shares that is convertible into Mycotopia common stock equal to 5% of the value of all the consideration, including any stock, cash or
debt of such completed transaction for Mycotopia. A &#x201c;Significant Transaction&#x201d; shall mean a financing of at least $&lt;span id="xdx_90F_eus-gaap--PaymentForContingentConsiderationLiabilityFinancingActivities_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zuBDibIKHEyl" title="Payment for contingent consideration"&gt;500,000&lt;/span&gt;
or the closing of an acquisition with a valuation of at least $&lt;span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zsXZP5TmroN1" title="Payment of consideration for rendered services"&gt;1,000,000&lt;/span&gt; for Mycotopia. For the year ending December 31, 2021, the Company
did not grant any equity in relation to a Significant Transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2021, no amounts have been accrued related to the bonuses.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Consulting
Agreement with CFO&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
October 1, 2020, the Company entered into a consulting agreement with the Company&#x2019;s CFO, James Cardwell for an initial term of
one year, which was extended for an additional year upon its anniversary. Compensation pursuant to the agreement shall be a minimum of
$&lt;span id="xdx_909_eus-gaap--CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1_iI_c20211231_zMd3saVbJnSc" title="Minimum payments"&gt;1,500&lt;/span&gt; per month. As of December 31, 2021 and 2020, the Company has accrued $&lt;span id="xdx_907_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20211231_zYvprCw2kVY2" title="Accrued expense"&gt;16,500&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20201231_zUgbq7PQfzQg"&gt;4,500&lt;/span&gt;, respectively, as accrued expense in relations
to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Consulting
Agreement with Chief Technology Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 1, 2020, the Company entered into an executive employment agreement with the Chief Technology Officer. The Company shall pay
the executive $&lt;span id="xdx_90B_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20200102__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zeyCaAP55WGh" title="Annual service"&gt;120,000&lt;/span&gt; annually for services rendered. During the year ended December 31, 2021, the Company issued &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20211231_zUEzRmakBhyc" title="Issuance of common stock"&gt;2,033,016&lt;/span&gt; shares of
common stock with a fair value of $&lt;span id="xdx_90F_eus-gaap--AdvancesFairValueDisclosure_iI_c20211231_zJLOjQ2DGTTf" title="Common stock fair value"&gt;130,113&lt;/span&gt;. As of December 31, 2021 and 2020, the Company recorded $&lt;span id="xdx_901_eus-gaap--CostsAndExpenses_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChiefTechonologyOfficerMember_zTSIzKLxBPf" title="Accrued expenses"&gt;138,360&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--CostsAndExpenses_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ChiefTechonologyOfficerMember_zHIjZF001oxh"&gt;129,180&lt;/span&gt; as accrued expenses
related to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteThreeMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">11000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteThreeMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">1000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteThreeMember"
      decimals="INF"
      id="Fact000808"
      unitRef="Shares">110000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteThreeMember"
      decimals="INF"
      id="Fact000810"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockDividendsShares
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">110000</us-gaap:CommonStockDividendsShares>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-08-032020-08-04_us-gaap_RelatedPartyMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">775194</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-08-032020-08-04_custom_DirectorsMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">775194</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-01-012021-01-02_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember"
      id="Fact000818">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000820"
      unitRef="USD">210900</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000822"
      unitRef="USD">320000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">3157789</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">1874963</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">1691226</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">2194963</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PaymentsToEmployees
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000832"
      unitRef="USD">517500</us-gaap:PaymentsToEmployees>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2019-06-232019-06-24_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember"
      id="Fact000834">P24M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-04-16_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember"
      decimals="INF"
      id="Fact000836"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2020-04-16_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember"
      id="Fact000838">2022-04-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_BenjaminKaplanMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">3358498</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember"
      decimals="0"
      id="Fact000842"
      unitRef="USD">720695</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">1000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-01-012021-01-02_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember"
      id="Fact000847">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">24000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">288000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000851">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zjkKxneFkRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following EBITDA milestones. For the year
ending December 31, 2021, no EBITDA milestones were met and no amounts have been recorded for the bonus milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B7_zJJp43T5yRu7" style="display: none"&gt;SCHEDULE
OF BONUS AND MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus
    (Canadian Dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;EBITDA
    Milestones (Canadian Dollars)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 40%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zyqifyjtB7T5" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 56%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;1&lt;sup&gt;st
    &lt;/sup&gt;$&lt;span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember_zERmxAD2OCwh" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zxPo2QkPlvVc"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;2&lt;sup&gt;nd
    &lt;/sup&gt;$&lt;span id="xdx_90E_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember_zH6FBzSbrnJg"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zBh1b2i6K0Qj"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;3&lt;sup&gt;rd
    &lt;/sup&gt;$&lt;span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember_ziiK0GmQG0R1"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zeUUPl0HJ957"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;4&lt;sup&gt;th
    &lt;/sup&gt;$&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember_ziWQA0jQI0u4"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_uCAD_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zN5PmOdmdYz5"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;5&lt;sup&gt;th
    &lt;/sup&gt;$&lt;span id="xdx_907_ecustom--RevenueRecognitionMilestoneMethod_uCAD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember_zoSKPsJIyTpe" title="EBITDA Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusOneMember"
      decimals="0"
      id="Fact000853"
      unitRef="CAD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesOneMember"
      decimals="0"
      id="Fact000855"
      unitRef="CAD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusTwoMember"
      decimals="0"
      id="Fact000856"
      unitRef="CAD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesTwoMember"
      decimals="0"
      id="Fact000857"
      unitRef="CAD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusThreeMember"
      decimals="0"
      id="Fact000858"
      unitRef="CAD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesThreeMember"
      decimals="0"
      id="Fact000859"
      unitRef="CAD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusFourMember"
      decimals="0"
      id="Fact000860"
      unitRef="CAD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesFourMember"
      decimals="0"
      id="Fact000861"
      unitRef="CAD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusFiveMember"
      decimals="0"
      id="Fact000862"
      unitRef="CAD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesFiveMember"
      decimals="0"
      id="Fact000864"
      unitRef="CAD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000866">&lt;p id="xdx_893_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zdyOOOaagc74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Market Capitalization by maintaining
the below market cap for a period of 22 consecutive trading days:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BC_zQsWSfHCx7Zc" style="display: none"&gt;SCHEDULE
OF BONUS AND MARKET CAPITALIZATION MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus
    (Shares)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    Capitalization Milestone (U.S. Dollars)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98F_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember_zTC7LBZqvwg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 41%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 54%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember_zQuyMa50iioj"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember_zkZpGnShiQoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember_zmHPa3NpaURc"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98D_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember_zbpj6AEICy8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember_zu9cVbuPKXC"&gt;60,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember_zc53F3qNrRWb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember_zzNrcLEyAHU3" title="Market Capitalization Milestone"&gt;80,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_987_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember_zkpS9cN0kXdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--RevenueRecognitionMilestoneMethod_uUSD_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember_zEJQ4hy4S01a" title="Market Capitalization Milestone"&gt;100,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusOneMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Shares">5000000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesOneMember"
      decimals="0"
      id="Fact000868"
      unitRef="USD">20000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusTwoMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">5000000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesTwoMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">40000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusThreeMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">5000000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesThreeMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">60000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusFourMember"
      decimals="INF"
      id="Fact000873"
      unitRef="Shares">5000000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFourMember"
      decimals="0"
      id="Fact000875"
      unitRef="USD">80000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusFiveMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">5000000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFiveMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">100000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000880"
      unitRef="USD">250000</us-gaap:OperatingLeasePayments>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">1282826</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000883"
      unitRef="USD">1874963</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">3157789</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000885"
      unitRef="USD">1874963</us-gaap:InterestExpenseDebt>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000886"
      unitRef="USD">1282826</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_custom_ExecutiveConsultingAgreementMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">1874963</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">288000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000891"
      unitRef="USD">2317861</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">2029861</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="INF"
      id="Fact000895"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      id="Fact000897">2023-11-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">812118</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">2029861</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="From2021-01-012021-12-31_custom_MycotopiaMember"
      id="Fact000903">&lt;p id="xdx_898_eus-gaap--ScheduleOfDebtTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zqgOnLNSHdt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company will &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;pay
the CEO a bonus in Mycotopia restricted stock or restricted stock units based on the following EBITDA milestones. For the year ending
December 31, 2021, no EBITDA milestones were met, and no amounts have been recorded for the bonus milestones.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B3_zFYU8omL00F1" style="display: none"&gt;SCHEDULE
OF BONUS AND MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;EBITDA Milestones&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zZOK7ixDxO76" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;sup&gt;st&#160;&lt;/sup&gt;$&lt;span id="xdx_90A_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zAzTsBYMxlEb" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z2HGvpWSczo7" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;sup&gt;nd&#160;&lt;/sup&gt;$&lt;span id="xdx_90D_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zLzLeDET2ga3" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zBcbEvbsZwUi" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;sup&gt;rd&#160;&lt;/sup&gt;$&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_znpoWkz3Pofb" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zknu04Yws25f" title="Bonus"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4&lt;sup&gt;th&#160;&lt;/sup&gt;$&lt;span id="xdx_90C_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zAiwOxRgb3Oc" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--AccruedBonusesCurrent_iI_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zNGBUufhUhPb"&gt;100,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;sup&gt;th&#160;&lt;/sup&gt;$&lt;span id="xdx_900_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MilestonesFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zYnPRCnWKa73" title="Milestones"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusOneMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesOneMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusTwoMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesTwoMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusThreeMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000913"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesThreeMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusFourMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesFourMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2021-12-31_custom_BonusFiveMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrent>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MilestonesFiveMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">1000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
      contextRef="From2021-01-012021-12-31_custom_MycotopiaMember"
      id="Fact000924">&lt;p id="xdx_89E_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zsOxn9MN936k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following Mycotopia market capitalization
by maintaining the below market cap for Mycotopia for a period of 22 consecutive trading days:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B5_z66kon1cClug" style="display: none"&gt;SCHEDULE
OF BONUS AND MARKET CAPITALIZATION MILESTONES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;Bonus (Shares)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Market Capitalization Milestone&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_984_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zSHg0NOOdhp6" style="width: 41%" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 54%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z1loD84Y3v4g" title="Market Capitalization Milestone"&gt;30,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_984_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zxmHN03BLKO7" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zi0ZuDNxeKb7" title="Market Capitalization Milestone"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_988_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zSKFOkd2BFGh" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z6lbaChMdMP4" title="Market Capitalization Milestone"&gt;60,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_98E_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zrYAZIxgIUpa" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFourMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z9JSK54ReQ43" title="Market Capitalization Milestone"&gt;80,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98C_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--BonusFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_z8nh8QDjM6Vh" title="Bonus"&gt;&lt;span style="font-size: 10pt"&gt;250,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RevenueRecognitionMilestoneMethod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--MarketCapitalizationMilestonesFiveMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MycotopiaMember_zXpEB65X9kdb" title="Market Capitalization Milestone"&gt;100,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusOneMember_custom_MycotopiaMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesOneMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">30000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusTwoMember_custom_MycotopiaMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesTwoMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">40000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusThreeMember_custom_MycotopiaMember"
      decimals="INF"
      id="Fact000934"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesThreeMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">60000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusFourMember_custom_MycotopiaMember"
      decimals="INF"
      id="Fact000938"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFourMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000940"
      unitRef="USD">80000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_custom_BonusFiveMember_custom_MycotopiaMember"
      decimals="INF"
      id="Fact000942"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <EHVVF:RevenueRecognitionMilestoneMethod
      contextRef="From2021-01-012021-12-31_custom_MarketCapitalizationMilestonesFiveMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">100000000</EHVVF:RevenueRecognitionMilestoneMethod>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="From2021-01-012021-12-31_custom_ExecutiveConsultingAgreementMember_custom_BenjaminKaplanMember_srt_MinimumMember_custom_MycotopiaMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">1000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000950"
      unitRef="USD">1500</us-gaap:CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000952"
      unitRef="USD">16500</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">4500</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-01-02_us-gaap_ServiceMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">120000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">2033016</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AdvancesFairValueDisclosure
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000959"
      unitRef="USD">130113</us-gaap:AdvancesFairValueDisclosure>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-01-012021-12-31_custom_ChiefTechonologyOfficerMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">138360</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2020-01-012020-12-31_custom_ChiefTechonologyOfficerMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">129180</us-gaap:CostsAndExpenses>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000964">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zEFbCBoqK4N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;5.
&lt;span id="xdx_822_zUffHR9c4Mx7"&gt;PROMISSORY NOTE AND CONVERTIBLE PROMISSORY NOTES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Convertible
Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the years ended December 31, 2021 and 2020, the Company issued convertible promissory notes (the &#x201c;Notes&#x201d;) with a term of
&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zS8VZCMRuXr8"&gt;18
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and 24&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
&lt;span style="color: Black"&gt;months upon issuance. &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zdNgn9U7aFoe"&gt;The
Notes were issued with an original issue discount (an &#x201c;OID&#x201d;) of 10%, and mature beginning April 2022 thru December 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt; &lt;/span&gt;&lt;span style="color: Black; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At December 31, 2021 the Notes are
convertible into &lt;span id="xdx_90C_eus-gaap--ExcessStockSharesIssued_iI_pid_c20211231_zaD5ulnuihA6"&gt;148,428,343 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares
of the Company&#x2019; common stock and &lt;span id="xdx_90F_eus-gaap--ExcessStockSharesIssued_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--MycotopiaCommonStocksMember_zJDnAUy9UBxe"&gt;1,007,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of Mycotopia common stock.
During the years ended December 31, 2021 and 2020, the Company issued &lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zmMJYRAWApHl"&gt;141,635,524
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zB7nsshFXK22"&gt;37,818,154&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
respectively, shares of common stock upon conversion of the Notes and accrued interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_zjxEjYiPKoQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B7_zHIaVpXMzXXl" style="display: none"&gt;SCHEDULE
OF NOTES PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of &lt;br/&gt;
December 31,2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zmf5czgGQtoh" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuances&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20200101__20201231_zaQ9rh85dANb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,544,487&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversions&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ConversionsOfNotesPayable_c20200101__20201231_zdXQbz1rIH5c" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(378,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20201231_zPqKabgSVcQf" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,407,582&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of original issue discount (interest expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_ztFab3vAtdq5" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;804,356&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of BCF and warrants (amortization expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20200101__20201231_zBuq7PHefDU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;91,992&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_zrf4uyY8dyNa" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;655,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuances&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20210101__20211231_zn5MWLcRM5Id" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,768,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversions
    (not inclusive of accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zQN4XiTGIYpj" title="Accrued interest"&gt;44,104&lt;/span&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ConversionsOfNotesPayable_c20210101__20211231_zXhBO6vRf4Ie" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,424,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20211231_zLpnfGkdIQPj" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,054,904&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231_zU8LxMGcmsO6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,364,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zVRDsuxIK7kk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,111&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zPfAOUYNYGc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Promissory
Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
December 20, 2021, the Company entered into a settlement agreement to apply the $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerRefundLiability_iI_c20211220_zM3L5O2bbM45"&gt;302,637
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;tax refund from Ontario Interactive
Digital Media Tax Credit as payment for the promissory note recorded in the amount of $&lt;span id="xdx_90E_eus-gaap--NotesPayableCurrent_iI_c20201231_zhY9x6WKTCQ8"&gt;349,079
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;as of December 31, 2020. In connection
with the settlement, previous amounts of principal and accrued interest due under the promissory note were forgiven in the aggregate
amount of $&lt;span id="xdx_900_eus-gaap--NotesPayable_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zKrTS7tZbXa4"&gt;350,739&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
As part of the settlement, the Company agreed to compensate the lenders and issue $&lt;span id="xdx_90A_eus-gaap--StockIssued1_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zy80EtMVWTtb"&gt;50,569
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;worth of common stock. The $&lt;span id="xdx_906_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteMember_zTX9IPB2RTlk" title="Accounts payable and accrued expense"&gt;50,569&lt;/span&gt;
has been recorded as accounts payable and accrued expense as of December 31, 2021. For the year ended December 31, 2021, the Company
recorded in its consolidated statements of operations a loss on settlement of debt in the amount of $&lt;span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20210101__20211231_zm8KCAzZlv5a"&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteMember"
      id="Fact000965">P18M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteMember"
      id="Fact000966">The
Notes were issued with an original issue discount (an &#x201c;OID&#x201d;) of 10%, and mature beginning April 2022 thru December 2023.</us-gaap:DebtInstrumentDescription>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">148428343</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_custom_MycotopiaCommonStocksMember"
      decimals="INF"
      id="Fact000968"
      unitRef="Shares">1007500</us-gaap:ExcessStockSharesIssued>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">141635524</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">37818154</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ScheduleOfDividendsPayableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact000972">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDividendsPayableTextBlock_zjxEjYiPKoQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table summarizes the Notes activity during the years ended December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8B7_zHIaVpXMzXXl" style="display: none"&gt;SCHEDULE
OF NOTES PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of &lt;br/&gt;
December 31,2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iS_c20200101__20201231_zmf5czgGQtoh" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 78%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuances&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20200101__20201231_zaQ9rh85dANb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,544,487&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversions&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ConversionsOfNotesPayable_c20200101__20201231_zdXQbz1rIH5c" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(378,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20201231_zPqKabgSVcQf" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,407,582&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of original issue discount (interest expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_ztFab3vAtdq5" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;804,356&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of BCF and warrants (amortization expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20200101__20201231_zBuq7PHefDU7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;91,992&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iS_c20210101__20211231_zrf4uyY8dyNa" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;655,071&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuances&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_c20210101__20211231_zn5MWLcRM5Id" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,768,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversions
    (not inclusive of accrued interest of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231_zQN4XiTGIYpj" title="Accrued interest"&gt;44,104&lt;/span&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ConversionsOfNotesPayable_c20210101__20211231_zXhBO6vRf4Ie" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,424,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_c20211231_zLpnfGkdIQPj" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,054,904&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231_zU8LxMGcmsO6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Amortization of debt discount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,364,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible
    promissory notes, balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iE_c20210101__20211231_zVRDsuxIK7kk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Convertible promissory notes, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,111&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDividendsPayableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000976"
      unitRef="USD">2544487</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <EHVVF:ConversionsOfNotesPayable
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000978"
      unitRef="USD">-378182</EHVVF:ConversionsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">2407582</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000982"
      unitRef="USD">804356</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000984"
      unitRef="USD">91992</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact000986"
      unitRef="USD">655071</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000988"
      unitRef="USD">1768700</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000990"
      unitRef="USD">44104</us-gaap:InterestPayableCurrentAndNoncurrent>
    <EHVVF:ConversionsOfNotesPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000992"
      unitRef="USD">-1424900</EHVVF:ConversionsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000994"
      unitRef="USD">2054904</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact000996"
      unitRef="USD">2364334</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">1309111</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="AsOf2021-12-20"
      decimals="0"
      id="Fact000999"
      unitRef="USD">302637</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact001000"
      unitRef="USD">349079</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">350739</us-gaap:NotesPayable>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-12-31_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001002"
      unitRef="USD">50569</us-gaap:StockIssued1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">50569</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact001005"
      unitRef="USD">480</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001007">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmN8yrCVdPN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;6.
&lt;span id="xdx_823_zHLoWLV3Jl41"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="text-decoration: underline"&gt;Collaboration
Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2021 and 2020, the Company recorded
$&lt;span id="xdx_904_eus-gaap--RoyaltyExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zKKC01E9kzt5" title="Annual royalty"&gt;10,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z8weR8EACvhd" title="Annual royalty"&gt;5,000&lt;/span&gt;, respectively, for the annual royalty due under the terms of the collaboration agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="text-decoration: underline"&gt;Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant
$&lt;span id="xdx_900_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqch94Fy5uW2" title="Payment for consultants"&gt;6,500&lt;/span&gt; per month for services rendered to be paid $&lt;span id="xdx_900_eus-gaap--RepaymentsOfOtherDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zULfZQpqsnP" title="Debt paid in cash"&gt;2,500&lt;/span&gt; in cash and $&lt;span id="xdx_905_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmAB3YIZyxb7" title="debt common shares, value"&gt;4,000&lt;/span&gt; in common shares of the Company to be valued at a &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20200102__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJRjzuQg0wF5" title="Debt percentage"&gt;20&lt;/span&gt;% discount
to the lowest trading price for the five trading days prior to date upon which payment is due. As of December 31 2021 and 2020, the Company
recorded $&lt;span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z8FytkTamZw1" title="Accrued expense"&gt;75,966&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zqpLCrvV1Ho6" title="Accrued expense"&gt;79,159&lt;/span&gt; as accrued expenses related to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
November 16, 2021, the Company entered into a consulting agreement for a term of three years to advise the Company and its Ketadash Subsidiary
(see &#x201c;Subsequent Events&#x201d;) in establishing services to be provided in California. The Company will pay the consultant a percentage
of gross profits as follows: &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20211115__20211116__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zGjGjPnX5Fsi" title="Debt description"&gt;(i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and
(iii) 5% for gross profits exceeding $5,000,001.&lt;/span&gt; As of December 31, 2021 and the date of this filing, no amounts have been earned under
this contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Medical
Advisory Board Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the period ended December 31, 2020, the Company entered into medical advisory board agreements with four members for a term of one year
each. As consideration for the services to be rendered, the Company agreed to pay $&lt;span id="xdx_906_eus-gaap--RepaymentsOfOtherDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zxINacV1yvJb"&gt;45,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;in cash and $&lt;span id="xdx_907_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwRiRIclaUul"&gt;155,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;worth of common stock. As of December
31, 2021 and 2020, the Company has accrued $&lt;span id="xdx_907_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zto7lbZ5pthb"&gt;233,110
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;and $&lt;span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--MedicalAdvisoryBoardAgreementsMember_zU1CmkqFG8lj"&gt;105,438
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;in relation to these agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-12-31_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">10000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-12-31_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">5000</us-gaap:RoyaltyExpense>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-012020-01-02_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">6500</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2020-01-012020-01-02_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">2500</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-012020-01-02_custom_CollaborationAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">4000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2020-01-02_custom_CollaborationAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">75966</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember"
      decimals="0"
      id="Fact001023"
      unitRef="USD">79159</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2021-11-152021-11-16_custom_CollaborationAgreementMember"
      id="Fact001025">(i) 10% of gross profits up to $1,000,000, (ii) 7.5% of gross profits from $1,000,001 to $5,000,000, and
(iii) 5% for gross profits exceeding $5,000,001.</us-gaap:DebtInstrumentDescription>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2020-01-012020-12-31_custom_MedicalAdvisoryBoardAgreementsMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">45000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-012020-12-31_custom_MedicalAdvisoryBoardAgreementsMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001027"
      unitRef="USD">155000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_custom_MedicalAdvisoryBoardAgreementsMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">233110</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_custom_MedicalAdvisoryBoardAgreementsMember"
      decimals="0"
      id="Fact001029"
      unitRef="USD">105438</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001031">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgmzX1AyQ7c4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;7.
&lt;span id="xdx_82E_zvr8oPqoIfKc"&gt;STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
September 15, 2020, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember_zGnisc7rGsIj" title="Common stock issued, shares"&gt;1,050,000&lt;/span&gt; shares of common stock in accordance with a strategic alliance agreement and as consideration
for the purchase of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zfAndyFoFgGj" title="Common stock purchase, shares"&gt;1,050,000&lt;/span&gt; share of Psychedelitech, Inc. (&#x201c;Psychedelitech&#x201d;) (a private Ontario corporation). As a result
of the transaction, the Company purchased &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PsychedelitechIncMember_zUHV2PCEWXbl" style="font: 10pt Times New Roman, Times, Serif" title="Equity percentage"&gt;10&lt;/span&gt;% of Psychedelitech. The shares were recorded at fair value on the date of issuance of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zrBYU3CBwha" title="Common stock fair value issued"&gt;26,250&lt;/span&gt;.
As of December 31, 2021 and 2020, the investment in Psychedelitech is recorded at cost in the amount of $&lt;span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_z4EWDXcRziCd" title="Cost of the investment"&gt;&lt;span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__dei--LegalEntityAxis__custom--PsychedelitechIncMember_zzd3UMJOkAR1"&gt;26,250&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zW92W1JbrEr" title="Conversion of common stock shares"&gt;37,818,154&lt;/span&gt; shares of common stock, in the aggregate, upon conversion of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z6FGh0cB3Wjj" title="Conversion of common stock, value"&gt;378,182&lt;/span&gt;
of convertible promissory notes (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightExercised_iI_c20201231_zkKxIAZW7gI4" title="Number of warrants exercised"&gt;100,909&lt;/span&gt; shares of common stock upon the cashless exercise of &lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightExercised_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6oL2Agyz3K2" title="Number of warrants exercised"&gt;110,000&lt;/span&gt; warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
December 31, 2020, the Company issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201230__20201231__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z3LLWTfuOHCb"&gt;353,622
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of common stock in relation
to an asset sale and purchase agreement entered into on January 21, 2021 with CureDash, Inc. (a Deleware Corporation) (&#x201c;CureDash&#x201d;
or the &#x201c;Seller&#x201d;). The shares were recorded at fair value on the date of issuance of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z7sMo612LQ5"&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet. On January 21, 2021,
the Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase
price of the assets was $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember_z8CnjFB7yLik"&gt;100,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;payable with the issuance of the
&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb11h3d8rlOb"&gt;353,622
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of common stock and $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210120__20210121__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYCdDXB72Sd4"&gt;60,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;in cash which was paid upon closing
on January 21, 2021. As of December 31, 2021, the Company recorded the purchase as an asset acquisition and recorded $&lt;span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetSaleAndPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgvyBZajC1c"&gt;100,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;as fixed assets where were impaired
during the year ended December 31, 2021 (see Note 1, Property and Equipment).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (&#x201c;20/20 Global&#x201d;)
that provide for: (i) 20/20 Global&#x2019;s purchase for $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zM9OinbzzIxg" title="Purchase of shares, value"&gt;350,000&lt;/span&gt; in cash of all of the outstanding stock of Mycotopioa Therapies, Inc.
(&#x201c;MYC&#x201d;), the Company&#x2019;s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming
a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global&#x2019;s board of directors and management.
In a related transaction, Ehave agreed to purchase &lt;span id="xdx_90C_ecustom--PaymentsToAcquireEquitySecuritiesShares_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zf7669AZabL1" title="Purchase of shares"&gt;9,793,754&lt;/span&gt; shares of 20/20 Global common stock from third parties, which constitutes
approximately &lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210119__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_ziK8dzz2q8Me" title="Equity percentage"&gt;75.77&lt;/span&gt;% of the issued and outstanding shares of 20/20 Global&#x2019;s common stock, for $&lt;span id="xdx_901_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhJVSFf4TXv8" title="Purchase of shares, value"&gt;350,000&lt;/span&gt; in cash. There was a change
in control of 20/20 Global&#x2019;s board of directors and the transaction was accounted for as a reverse merger in which Mycotopia Therapies,
Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer. The Company acquired a controlling interest in 20/20
Global, changed its name to Mycotopia Therapies, Inc. (&#x201c;Mycotopia&#x201d;), and consolidated Mycotopia as of December 31, 2021.
The Company recorded a non-controlling interest in the amount of negative $&lt;span id="xdx_908_eus-gaap--NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_c20210118__20210119__srt--TitleOfIndividualAxis__custom--FormerAndCurrentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqORO7pDR9F8" title="Non controlling interest"&gt;3,454&lt;/span&gt; for the disposal of MYC and re-acquisition of Mycotopia.
The purpose of this transaction was to monetize the Company&#x2019;s subsidiary into a publicly traded company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2021, the Company received aggregate investments of $&lt;span id="xdx_90B_ecustom--InvestmentReceived_c20210101__20211231_zyZrXh9AHOEc" title="Investment received"&gt;1,502,000&lt;/span&gt; and issued &lt;span id="xdx_901_ecustom--InvestmentReceivedShares_c20210101__20211231_zyZj8RyziDba" title="Investment received shares"&gt;22,682,142&lt;/span&gt; shares of common stock,
in the aggregate, from Regulation A Offerings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqdPZT499Zh1" title="Common stock issued, shares"&gt;5,681,985&lt;/span&gt; shares of common stock upon the cashless exercise of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z24MXcH38Tc1" title="Common stock issued warrant, shares"&gt;6,709,890&lt;/span&gt; warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteAndAccruedInterestMember_zGlGmNzxDEOj"&gt;141,635,524
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of common stock, in the
aggregate, upon the conversion of convertible promissory notes and accrued interest in the amount of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteAndAccruedInterestMember_zvfkRar5wsFg"&gt;1,469,004&lt;/span&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;in the aggregate. (see Note
5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;STOCK
BASED COMPENSATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company entered into a finder&#x2019;s fee agreement with a consultant to assist the Company in
procuring sources of financing such as equity, debt, or a merger or sale of the Company. &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_z6Oq543aD7ll" title="Compensation for services description"&gt;Total compensation for the consultant&#x2019;s
efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total
shares of common stock purchased or convertible equivalent.&lt;/span&gt; During the year ending December 31, 2020, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zjvrHjve6oW5" title="Stock issued, shares"&gt;1,250,000&lt;/span&gt; shares
of common stock which was recorded at fair value of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zRFWMxfNRfn7" title="Stock issued"&gt;46,875&lt;/span&gt; and paid $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--FindersFeeAgreementMember_zyV7UO60qKBh" title="Stock based compensation expense"&gt;63,500&lt;/span&gt; in relation to the finder&#x2019;s fee agreement. The Company
recognized these amounts as interest expense in the Company&#x2019;s consolidated statements of operations and other comprehensive loss
during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zZgCT2NgyYl4" title="Shares issued upon exercise of warrants"&gt;3,358,498&lt;/span&gt; vested warrants to Ben Kaplan, the Company&#x2019;s CEO, in accordance
with his employment agreement valued at $&lt;span id="xdx_90D_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z0p0lih1ZPN9" title="Warrants issued during period, value"&gt;720,695&lt;/span&gt;. The Company expensed $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_z9K47AzlUPHd" title="General and administrative expenses"&gt;720,695&lt;/span&gt; as general and administrative expense in relation to
this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock
prices of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zkn23SGTrM37" title="Stock price"&gt;0.37&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zPSfGAttRPC5" title="Stock price"&gt;0.12&lt;/span&gt;, b) exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember_zBqBYMwu8sZ2" title="Warrants exercise price"&gt;0.01&lt;/span&gt;, c) dividend rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zEQJM1BOKdhi" title="Dividend rate"&gt;0&lt;/span&gt;%, d) risk free rates of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zUAEKCVD7DAl" title="Risk-free interest rate"&gt;0.20&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zTq8XPRoOhp9" title="Risk-free interest rate"&gt;0.13&lt;/span&gt;%, and e) expected
volatility of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MaximumMember_zxxRV9eDHc0e" title="Expected volatility"&gt;570&lt;/span&gt;% and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BenjaminKaplanMember__srt--RangeAxis__srt--MinimumMember_zylceUgHbaY7" title="Expected volatility"&gt;648&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zb6vk9IGSVAk" title="Number of stock issued for services"&gt;1,183,357&lt;/span&gt; shares of common stock, in the aggregate to consultants for services rendered.
The Company expensed $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zlgZsEzu3LX5" title="Stock based compensation expense"&gt;161,225&lt;/span&gt;, in the aggregate, in relation to this issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ending December 31, 2021, the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EhaveMember_z0MPP0HMWHpd"&gt;7,354,312
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of Ehave common stock for
services rendered and recorded $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EhaveMember_zhvwqnVIZ2Yd"&gt;654,647
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;in relation to these shares
issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;EHAVE,
                                            INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(Expressed
in U.S. Dollars)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December
31, 2021, the Company issued&#160;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__dei--LegalEntityAxis__custom--MycotopiaMember_zQPZIuApKz61" title="Vested"&gt;812,118&lt;/span&gt;&#160;vested Mycotopia warrants and recorded stock compensation of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MycotopiaConsultingAgreementMember_zOfOLmJU7sAd" title="Stock based compensation expensee"&gt;2,029,861&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the Company
recorded stock compensation of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231__dei--LegalEntityAxis__custom--MycotopiaMember_z1ggQQqOBZpl" title="Stock issued for services"&gt;2,252,000&lt;/span&gt; in relation to services rendered for Mycotopia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the
Company recorded stock compensation of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--AdvisoryMember_zRanCqSjbA2d"&gt;30,000
&lt;/span&gt;in relation to medical advisory board fees for services rendered for Mycotopia.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Warrants
Issued&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_znstxQtlpet" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021
and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zomrxm5uHCk6" style="display: none"&gt;SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zPvx7tzY2k23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_zAoPVYxy0sq1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Underlying Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,803,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zOQZHhGswFQd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zAqp2FQv0Ag7" title="Weighted average remaining contractual Life (Years), granted"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20200101__20201231_zCOn8XLsK783" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(110,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20200101__20201231_zy89pJwIVU1a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_zDRHQoXcmFca" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1135"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zoPtixTnwqX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,693,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zkiLgp4CsXmf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5Yje2NBvRWd" title="Weighted average remaining contractual Life (Years), beginning"&gt;1.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zQPqF9mFTqxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,337,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_za2zTaytXB79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z7csjRGBvGJj" title="Weighted average remaining contractual Life (Years), granted"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zQxjwRBR2oVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,709,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_z48PpC1pU7jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zLKR9WkOpsoh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_zXENby9aH0Ml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;29,320,478&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zxBraV8aHhw7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231_zy8MeWaGJ9ed" title="Weighted average remaining contractual Life (Years), ending"&gt;0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zP7Kcb661PK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
intrinsic value of warrants outstanding as of December 31, 2021 was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zFjJKkxPN2Q" title="Outstanding, intrinsic value, warrants"&gt;18,844&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_z6c677kY2hp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the
following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BA_zX0FAp6E6b05" style="display: none"&gt;SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term, in years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zbFtCQFfc98" title="Expected term, in years"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1DeD6o9wjS9" title="Expected term, in years"&gt;2.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zabF38jn0oll" title="Expected volatility"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zlvvIatxWoP5" title="Expected volatility"&gt;162.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zOiwngw6yitg" title="Risk free interest rate"&gt;0.09&lt;/span&gt;
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zRK6NYQmQHYj" title="Risk free interest rate"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zO685fyGsQH9" title="Risk-free interest rate"&gt;0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zymLJqCg9Sw7" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231_z2FzMMQ6TSuk" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zKlsyQ6LCJyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-09-142020-09-15_custom_StrategicAllianceAgreementMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-09-142020-09-15_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-09-15_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-09-142020-09-15_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember"
      decimals="0"
      id="Fact001039"
      unitRef="USD">26250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2021-12-31_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">26250</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2020-12-31_custom_StrategicAllianceAgreementMember_custom_PsychedelitechIncMember"
      decimals="0"
      id="Fact001042"
      unitRef="USD">26250</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001044"
      unitRef="Shares">37818154</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">378182</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <EHVVF:ClassOfWarrantOrRightExercised
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact001048"
      unitRef="Shares">100909</EHVVF:ClassOfWarrantOrRightExercised>
    <EHVVF:ClassOfWarrantOrRightExercised
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">110000</EHVVF:ClassOfWarrantOrRightExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-12-302020-12-31_custom_AssetSaleAndPurchaseAgreementMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">353622</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">353622</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-202021-01-21_custom_AssetSaleAndPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001055"
      unitRef="USD">60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="From2021-01-012021-12-31_custom_AssetSaleAndPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001056"
      unitRef="USD">100000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember"
      decimals="0"
      id="Fact001058"
      unitRef="USD">350000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <EHVVF:PaymentsToAcquireEquitySecuritiesShares
      contextRef="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">9793754</EHVVF:PaymentsToAcquireEquitySecuritiesShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Pure">0.7577</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">350000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2021-01-182021-01-19_custom_FormerAndCurrentDirectorsMember_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001066"
      unitRef="USD">3454</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <EHVVF:InvestmentReceived
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">1502000</EHVVF:InvestmentReceived>
    <EHVVF:InvestmentReceivedShares
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001070"
      unitRef="Shares">22682142</EHVVF:InvestmentReceivedShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001072"
      unitRef="Shares">5681985</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001074"
      unitRef="USD">6709890</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAndAccruedInterestMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Shares">141635524</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAndAccruedInterestMember"
      decimals="0"
      id="Fact001076"
      unitRef="USD">1469004</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2020-01-012020-12-31_custom_FindersFeeAgreementMember"
      id="Fact001078">Total compensation for the consultant&#x2019;s
efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total
shares of common stock purchased or convertible equivalent.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_custom_FindersFeeAgreementMember"
      decimals="INF"
      id="Fact001080"
      unitRef="Shares">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_custom_FindersFeeAgreementMember"
      decimals="0"
      id="Fact001082"
      unitRef="USD">46875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_custom_FindersFeeAgreementMember"
      decimals="0"
      id="Fact001084"
      unitRef="USD">63500</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_BenjaminKaplanMember"
      decimals="INF"
      id="Fact001086"
      unitRef="Shares">3358498</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember"
      decimals="0"
      id="Fact001088"
      unitRef="USD">720695</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember"
      decimals="0"
      id="Fact001090"
      unitRef="USD">720695</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-12-31_custom_BenjaminKaplanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001092"
      unitRef="USDPShares">0.37</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001094"
      unitRef="USDPShares">0.12</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_BenjaminKaplanMember"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Pure">0.0020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Pure">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001104"
      unitRef="Pure">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_custom_BenjaminKaplanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Pure">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_ConsultantMember"
      decimals="INF"
      id="Fact001108"
      unitRef="Shares">1183357</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember_custom_ConsultantMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">161225</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_EhaveMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Shares">7354312</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_custom_EhaveMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">654647</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_custom_MycotopiaMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">812118</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_MycotopiaConsultingAgreementMember"
      decimals="0"
      id="Fact001116"
      unitRef="USD">2029861</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31_custom_MycotopiaMember450651203"
      decimals="0"
      id="Fact001118"
      unitRef="USD">2252000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_AdvisoryMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">30000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001121">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_znstxQtlpet" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2021
and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zomrxm5uHCk6" style="display: none"&gt;SCHEDULE OF OUTSTANDING STOCK WARRANTS ACTIVITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231_zPvx7tzY2k23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231_zAoPVYxy0sq1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Underlying Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,803,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zOQZHhGswFQd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231_zAqp2FQv0Ag7" title="Weighted average remaining contractual Life (Years), granted"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20200101__20201231_zCOn8XLsK783" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(110,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_iN_di_c20200101__20201231_zy89pJwIVU1a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_zDRHQoXcmFca" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1135"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231_zoPtixTnwqX7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,693,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zkiLgp4CsXmf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5Yje2NBvRWd" title="Weighted average remaining contractual Life (Years), beginning"&gt;1.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231_zQPqF9mFTqxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,337,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_za2zTaytXB79" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z7csjRGBvGJj" title="Weighted average remaining contractual Life (Years), granted"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231_zQxjwRBR2oVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,709,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_z48PpC1pU7jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zLKR9WkOpsoh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrant
    outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20211231_zXENby9aH0Ml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underlying Shares, Warrants outstanding Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;29,320,478&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zxBraV8aHhw7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20211231_zy8MeWaGJ9ed" title="Weighted average remaining contractual Life (Years), ending"&gt;0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001125"
      unitRef="Shares">28803368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001127"
      unitRef="USDPShares">0.01</EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2020-01-012020-12-31" id="Fact001129">P1Y4M28D</EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001131"
      unitRef="Shares">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001133"
      unitRef="USDPShares">-0.01</EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact001137"
      unitRef="Shares">28693368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact001139"
      unitRef="USDPShares">0.01</EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-12-31" id="Fact001141">P1Y1M13D</EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001143"
      unitRef="Shares">7337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001145"
      unitRef="USDPShares">0.01</EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-12-31" id="Fact001147">P1Y6M</EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">6709890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001151"
      unitRef="USDPShares">0.01</EHVVF:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">29320478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001157"
      unitRef="USDPShares">0.01</EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-01to2021-12-31" id="Fact001159">P0Y5M8D</EHVVF:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001161"
      unitRef="USD">18844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001163">&lt;p id="xdx_89F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_z6c677kY2hp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
warrants granted during the period ending December 31, 2021 and 2020 were valued using the Black-Scholes option pricing model using the
following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;span id="xdx_8BA_zX0FAp6E6b05" style="display: none"&gt;SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS OF WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term, in years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zbFtCQFfc98" title="Expected term, in years"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z1DeD6o9wjS9" title="Expected term, in years"&gt;2.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zabF38jn0oll" title="Expected volatility"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_zlvvIatxWoP5" title="Expected volatility"&gt;162.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zOiwngw6yitg" title="Risk free interest rate"&gt;0.09&lt;/span&gt;
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zRK6NYQmQHYj" title="Risk free interest rate"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zO685fyGsQH9" title="Risk-free interest rate"&gt;0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zymLJqCg9Sw7" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231_z2FzMMQ6TSuk" style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</EHVVF:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-12-31" id="Fact001165">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31" id="Fact001167">P2Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001169"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001171"
      unitRef="Pure">1.6224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Pure">0.0009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001175"
      unitRef="Pure">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001177"
      unitRef="Pure">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001183">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_z594lxVfwa7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;8.
&lt;span id="xdx_820_zupYrNLBlFHg"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences
that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation
allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been
recorded for the years ended December 31, 2021 and December 31, 2020 due to the Company&#x2019;s operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2021, the Company has a net operating loss for tax purposes of CAD $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_uCAD_c20211231_z0gZzdrmQ2i2"&gt;15,824,709 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(2020
&#x2013; CAD $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_uCAD_c20201231_zfbx2sRDrKTh"&gt;11,448,330&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)
that can be &lt;span id="xdx_90C_ecustom--NetOperatingLossDescription_c20210101__20211231_ziz1czM5eEA1"&gt;carried forward over 20
years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;EHAVE, INC. AND SUBSIDIARIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;(Expressed in U.S. Dollars)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Deferred
Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Deferred
income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts for income tax purposes. The components of the Company&#x2019;s deferred taxes are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9jVIeZSsXxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B5_zt7f7Vh1Fqv8" style="display: none"&gt;SCHEDULE
OF COMPONENTS OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_490_20210101__20211231_z22wN7altAFi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49E_20200101__20201231_zV1psAqFMBZ7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iS_zARrTEoond2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax asset, beginning&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetIncreaseInValuationReserve_zB5V2PEEHz9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Increase
    in valuation reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,452,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iE_zH9IFCturMT7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax asset, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_zbm3h2QNqi0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iE_zBjAtVkuuxyf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zef0vh2O4dd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the significant differences between the Canadian Federal statutory tax rate and the Company&#x2019;s effective
tax rate for financial statement purposes for the years ended December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zR32WPNXNgP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zUe7Lwcvntf8" style="display: none"&gt;SCHEDULE
OF EFFECTIVE TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_zRisBdhnf8xe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200101__20201231_zSlSM9GjHzQ1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate_pid_dp_uPure_zbzeioKFyfNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Canadian statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15.00&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15.00&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate_pid_dp_uPure_zx0Pt7YN5jMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Provincial income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_zaRfspPTAk74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate_pid_dp_uPure_zyplKplwqnRc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amortization of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.09&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate_pid_dp_uPure_zqNn3LD8j4i4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate_pid_dp_uPure_zGlc5hTbjVZk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zBrbYVdZ1z2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.33&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate_pid_dp_uPure_zuu1aP9YzHsf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Foreign Exchange Rate Change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.53&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_znpil7XJs73f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zvPlaODmid1l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zNJPEQSsiHAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tax years from 2021 to 2023 are open for examination by the Canada tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001184"
      unitRef="CAD">15824709</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact001185"
      unitRef="CAD">11448330</us-gaap:OperatingLossCarryforwards>
    <EHVVF:NetOperatingLossDescription contextRef="From2021-01-01to2021-12-31" id="Fact001186">carried forward over 20
years.</EHVVF:NetOperatingLossDescription>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001188">&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9jVIeZSsXxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B5_zt7f7Vh1Fqv8" style="display: none"&gt;SCHEDULE
OF COMPONENTS OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_490_20210101__20211231_z22wN7altAFi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49E_20200101__20201231_zV1psAqFMBZ7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iS_zARrTEoond2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax asset, beginning&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetIncreaseInValuationReserve_zB5V2PEEHz9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Increase
    in valuation reserve&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,452,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;333,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iE_zH9IFCturMT7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax asset, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_di_zbm3h2QNqi0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,526,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iE_zBjAtVkuuxyf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact001190"
      unitRef="USD">1074000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="Fact001191"
      unitRef="USD">741000</us-gaap:DeferredTaxAssetsGross>
    <EHVVF:DeferredTaxAssetIncreaseInValuationReserve
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">2452000</EHVVF:DeferredTaxAssetIncreaseInValuationReserve>
    <EHVVF:DeferredTaxAssetIncreaseInValuationReserve
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact001194"
      unitRef="USD">333000</EHVVF:DeferredTaxAssetIncreaseInValuationReserve>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001196"
      unitRef="USD">3526000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">1074000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001199"
      unitRef="USD">3526000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="Fact001200"
      unitRef="USD">1074000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001205">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zR32WPNXNgP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zUe7Lwcvntf8" style="display: none"&gt;SCHEDULE
OF EFFECTIVE TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_zRisBdhnf8xe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200101__20201231_zSlSM9GjHzQ1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate_pid_dp_uPure_zbzeioKFyfNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Canadian statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15.00&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15.00&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate_pid_dp_uPure_zx0Pt7YN5jMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Provincial income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_zaRfspPTAk74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate_pid_dp_uPure_zyplKplwqnRc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amortization of debt discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.09&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate_pid_dp_uPure_zqNn3LD8j4i4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate_pid_dp_uPure_zGlc5hTbjVZk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zBrbYVdZ1z2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.33&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate_pid_dp_uPure_zuu1aP9YzHsf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Foreign Exchange Rate Change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.53&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_znpil7XJs73f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zvPlaODmid1l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001207"
      unitRef="Pure">0.1500</EHVVF:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001208"
      unitRef="Pure">0.1500</EHVVF:EffectiveIncomeTaxRateReconciliationAtCanadianStatutoryIncomeTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001210"
      unitRef="Pure">0.1205</EHVVF:EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001211"
      unitRef="Pure">0.0117</EHVVF:EffectiveIncomeTaxRateReconciliationAtProvincialIncomeTaxesNetOfFederalBenefitTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001213"
      unitRef="Pure">0.0009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001214"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001216"
      unitRef="Pure">-0.0309</EHVVF:EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001217"
      unitRef="Pure">-0.0820</EHVVF:EffectiveIncomeTaxRateReconciliationAtAmortizationOfDebtDiscountTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001219"
      unitRef="Pure">0.0000</EHVVF:EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001220"
      unitRef="Pure">0.1075</EHVVF:EffectiveIncomeTaxRateReconciliationAtDerivativesTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001222"
      unitRef="Pure">-0.0632</EHVVF:EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001223"
      unitRef="Pure">0.0000</EHVVF:EffectiveIncomeTaxRateReconciliationAtStockBasedCompensationTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001225"
      unitRef="Pure">-0.2133</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001226"
      unitRef="Pure">-0.2025</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001228"
      unitRef="Pure">0.0316</EHVVF:EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate>
    <EHVVF:EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001229"
      unitRef="Pure">0.0153</EHVVF:EffectiveIncomeTaxRateReconciliationAtForeignExchangeRateChangeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001231"
      unitRef="Pure">0.0044</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001232"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact001234"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact001235"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-12-31" id="Fact001237">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zJpXs63ASSKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;9.
&lt;span id="xdx_821_zj2QRE6qJZmg"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 8, 2022, the Company entered into a stock purchase agreement to acquire &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zriYokBYYyXl" title="Issued and outstanding shares, percentage"&gt;100&lt;/span&gt;% of the issued and outstanding shares of Rejuv IV,
Inc., a California company, (or &#x201c;Ketadash&#x201d;) from the seller (the &#x201c;Seller&#x201d;). The purchase price of the shares
is $&lt;span id="xdx_901_eus-gaap--BusinessCombinationConsiderationTransferred1_c20220107__20220108__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSl5JJQvJ648" title="Purchase price"&gt;250,000&lt;/span&gt; payable as follows: (i) $&lt;span id="xdx_900_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_c20220108__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLD8hksr3uCg" title="Cash"&gt;75,000&lt;/span&gt; in cash, and (ii) $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlYHaEtmmJu5" title="Stock issued during period value new issues"&gt;175,000&lt;/span&gt; of common stock valued at the average closing price for the five
trading days preceding January 8, 2022. As of the date of this filing, the Company paid &lt;span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--RejuvIvIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8SJlZESOfMd" title="Business acquisition percentage"&gt;100&lt;/span&gt;% of the purchase price, paid the $&lt;span id="xdx_905_eus-gaap--PaymentsToAcquireProductiveAssets_c20220107__20220108__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1fqj4DD58l4" title="Payment to acquire productive assets"&gt;75,000&lt;/span&gt;
in cash and issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220107__20220108__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zlJyp3WD2Doe" title="Stock issued during period shares new issues"&gt;19,977,169&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Subsequent
to year end, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3IBCIkttgqi" title="Stock issued during period conversion of convertible securities"&gt;15,800,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of common stock upon
the conversion of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9ho4KKCG9la" title="Stock issued during period value conversion of convertible securities"&gt;158,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;of convertible debt in accordance
with the terms of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Subsequent
to year end, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z55qM4hLYoz7" title="Stock issued during period for services, shares"&gt;5,055,381
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;to a consultant for services rendered
at a fair value of approximately $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmvaMFoiEW45" title="Stock issued during period for services, value"&gt;75,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Subsequent
to year end, the Company received &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220527__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--WesanaHealthHoldingsIncMember_zpF7XNjk2wIj"&gt;212,488
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of Wesana Health Holdings,
Inc. in exchange for all of the Company&#x2019;s Psytech shares.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_RejuvIvIncMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_RejuvIvIncMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001241"
      unitRef="USD">250000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2022-01-08_custom_RejuvIvIncMember_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001243"
      unitRef="USD">75000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001245"
      unitRef="USD">175000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2022-01-08_custom_RejuvIvIncMember_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001247"
      unitRef="Pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001249"
      unitRef="USD">75000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-072022-01-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">19977169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-05-27_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001253"
      unitRef="Shares">15800000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-05-27_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001255"
      unitRef="USD">158000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-05-27_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001257"
      unitRef="Shares">5055381</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-05-27_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">75000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-05-27_us-gaap_SubsequentEventMember_custom_WesanaHealthHoldingsIncMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Shares">212488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
